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Chapter 1  Introduction
Dystrophinopathies comprise a spectrum of muscle diseases caused by mutations in the 
DMD gene which codes for the muscle protein dystrophin. The clinical spectrum ranges 
from mild to severe and includes asymptomatic increase of serum concentration of creatine 
phosphokinase (hyperCKemia), X-linked myalgia/cramps with myoglobinuria, isolated 
quadriceps myopathy, X-linked cardiomyopathy, Becker muscular dystrophy (BMD) and 
Duchenne muscular dystrophy (DMD) (Darras et al., 2008).
The DMD gene is located in band Xp21.2 and the inheritance of dystrophinopathies is X-
linked. Mutations in the gene lead to absent or less functional dystrophin. The most common 
dystrophinopathy is DMD; its incidence varies between 1 in 3600 to 1 in 6000 (Emery, 
1991). The incidence in the Netherlands has been estimated to be 1 in 4200 live born males 
in the period 1961-1974 (van Essen et al., 1992b) and 1 in 4685 in the period 1993-2002 
(Helderman-van den Enden et al., 2012). The exact incidence of BMD is not known and has 
been estimated to be in the range of 1 in 12000 to 1 in 30000 male live births (Bushby et al., 
1991; Emery, 1991). 
Insufficient information is available on other dystrophinopathies. Results of immuno-
histochemical analysis of the muscle biopsy on individuals with hyperCKemia showed 
that 8% (3/40) of those without or with minimal symptoms showed abnormal dystrophin 
staining, resembling Becker pathology (Dabby et al., 2006), but molecular testing to confirm 
dystropinopathy was not done. Abnormal dystrophin staining was also seen in 8% (8/104) of 
clinically normal subjects with chronic hyperCKemia, but here molecular testing did confirm 
a form of dystrophinopathy (Fernandez et al., 2006). On the other hand, 27% (28/104) of 
patients with a mild X-linked muscular dystrophy phenotype who had abnormal dystrophin 
in the muscle biopsy, were sub-clinical or asymptomatic (Angelini et al., 1994). There are 
also a number of families/patients with X-linked myalgia and cramps (Gospe et al., 1989; 
Sanchez-Arjona et al., 2005; Veerapandiyan et al., 2010; Helderman-van den Enden et al., 
2010). At least 11 families have been published with X-linked dilated cardiomyopathy 
(Ferlini et al., 1999). However, only five patients with this type of dystrophinopathy were 
found among > 4700 mutations in the DMD gene reported in the Leiden DMD mutation 
database (Aartsma-Rus et al., 2006). No mutation was found in the DMD gene in 27 patients 
with idiopathic dilated cardiomyopathy without systemic disease (Michels et al., 1993). A 
recent study among 436 male patients with dilated cardiomyopathy showed a mutation in the 
DMD gene in 34 males (7,8%) (Diegoli et al., 2011). In conclusion, the incidence of other 
dystrophinopathies is not known as there is insufficient data, probably because many patients 
have not been diagnosed.
1.1  Clinical description 
1.1.1  Duchenne muscular dystrophy (DMD)
DMD is the most severe form of dystrophinopathy. In general, only males are affected due to 




of a translocation between an X-chromosome and an autosome where the normal X is 
preferentially inactivated. For other rare causes see Section 1.2 below: Dystropinopathy in 
women.
The affected boys do not show any symptoms at birth. More than half of the boys start 
walking only after 18 months, whereas 97% of normal children are already walking at this 
age (Emery and Muntoni, 2003). Most patients are diagnosed around the age of five, mainly 
because of delay in walking and an unsteady gait with tendency to walk on tiptoes. Some 
are diagnosed because a test for unrelated indications or calf pains reveals hyperCKemia 
or increased transaminases (Bushby et al., 1999; Emery and Muntoni, 2003). Proximal 
muscle weakness should be suspected if a boy has difficulties in running and climbing stairs 
and physical examination reveals hypertrophy of the calf muscles and a positive Gower’s 
sign (difficulty in getting up from the floor which is solved by spreading the legs and using 
the hands to climb up the thighs to get to an upright position). Serum CK concentration is 
typically increased to at least ten times normal till about the age of six (Darras et al., 2008); 
it then decreases with advancing age due to progressive loss of muscle mass (Zatz et al., 
1991). Most untreated DMD patients become wheelchair bound between the ages nine and 
twelve (Emery and Muntoni, 2003). Long-term corticosteroid therapy prolongs ambulation 
by two to five years and reduces the need for spinal stabilization surgery (Moxley et al., 
2010). Without treatment the muscle strength deteriorates and results in death around the 
age of 19. The survival can be prolonged into the fourth decade with corticosteroid, cardiac, 
respiratory, orthopaedic and rehabilitative interventions (Bushby et al., 2010a; Bushby et al., 
2010b; Eagle et al., 2002; Dreyer et al., 2010; Ishikawa et al., 2011). A typical clinical course 
can be seen in Figure 1.
 
Figure 1 
Musculoskeletal course in Duchenne muscular dystrophy (Verma et al., 2010) (with 
the kind permission of Professor Y Anziska). 
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When Duchenne de Boulogne first described these patients he noticed that, apart from 
the muscular dystrophy, some boys also had mental problems (Duchenne, 1868). Mental 
retardation (defined as full scale intelligence quotient below 70) has been estimated to occur 
in 19-35% of DMD cases (Cotton et al., 2001; Cotton et al., 2005). Cognitive impairment 
has been described also in patients with BMD although its frequency has not been studied 
systematically (Bardoni et al., 2000; North et al., 1996). In DMD patients the distribution of 
the IQ is shifted downward by approximately one standard deviation (Cotton et al., 2001) in 
comparison to the normal population. In contrast to the muscular dystrophy mental retardation 
is non-progressive (Anderson et al., 2002). Severe mental retardation is concordant in affected 
relatives (Muntoni et al., 2003), suggesting a primary role of the mutated DMD gene in mental 
retardation. Several authors have found that the loss of expression of dystrophin isoforms, 
especially DP140 and DP71, in the central nervous system is related to the retardation 
(Bardoni et al., 2000; Moizard et al., 1998; Taylor et al., 2010; Wingeier et al., 2011). The 
loss of DP71 is reported to result in a shift of two standard deviations of the Full Scale 
Intelligence Quotient (Daoud et al., 2009). If the mutation in the Dp140 isoform is located in 
the 5’ UTR, it has less effect on full scale intelligence quotient than if it is in the  promoter of 
protein-coding regions of Dp140 (Taylor et al., 2010).
1.1.2  Becker muscular dystrophy (BMD)
BMD is the second best known dystrophinopathy. The phenotype is less severe than DMD. 
As DMD, BMD is characterized by progressive symmetrical muscle weakness and atrophy, 
proximal greater than distal, often with calf hypertrophy. Preservation of the strength of 
the neck flexor muscle differentiates BMD from DMD. Wheelchair dependency, if present, 
occurs after the age of 16 in the natural course of the disease. However, as the corticosteroid 
therapy induces prolongation of the ambulation of DMD patients, the criterion of wheelchair 
dependency after the age of 16 does not always point to BMD. Occasional features of BMD 
are weakness of quadriceps femoris (sometimes the only sign), activity-induced cramping 
and late in the course flexion contractures of the elbows (Darras et al., 2008). Onset is 
usually between the ages of 5 and 15, however, it may occur later in life. The most frequent 
presenting symptom is calf pains, typically experienced in early teenage years, provoked 
by exercise and relieved by rest. Frequent falling and being slower than peers, can also be 
the presenting symptom (Bushby and Gardner-Medwin, 1993). Serum CK concentration is 
typically increased to more than five times the normal value, reaching the maximum on 
average between the ages of 10 and 15 (Zatz et al., 1991). The mean age of death is in the 
mid-40s with a large range (23-89 years) (Bushby and Gardner-Medwin, 1993) but many 
BMD patients with a mild phenotype who are still self supporting in their 60’s or 70’s have 
been described (Ferreiro et al., 2009; Helderman-van den Enden et al., 2010; Lesca et al., 




1.2  Dystrophinopathy in women 
1.2.1  Carriers
Most female carriers have no symptoms of dystrophinopathy because the inheritance of DMD 
is X-linked. Serum CK level is significantly raised in two-thirds of the carrier women (Emery 
and Muntoni, 2003) but without any symptoms. In two studies 2.5 to 7.8% of the female 
carriers developed symptoms varying from mild muscle weakness to a rapidly progressive 
DMD-like muscular dystrophy (Moser and Emery, 1974; Norman and Harper, 1989). 
A Dutch study of 129 female carriers reported frequent myalgia/cramps in 5% and muscle 
weakness in 17% (Hoogerwaard et al., 1999a). Dilated cardiomyopathy was present in 
5% and left ventricle dilatation in 18% (Hoogerwaard et al., 1999b). A recent follow-up 
study after nine years has shown that cardiac abnormalities in these carrier women are as 
progressive as in DMD patients (van Westrum et al., 2011). Carrier women are advised to 
start cardiac examination at the age of 16 or later, at diagnosis, with follow-up examinations 
every five years (Bushby et al., 2003). In the United States of America only 62.9% of the 
carriers appeared to be aware of their risk for cardiomyopathy (Bobo et al., 2009). In Scotland 
the benefit of routine cardiac surveillance of all carriers was questioned after the finding that 
there was no significant reduced life expectancy or higher risk of cardiac death in 94 deceased 
carriers compared to the general population (Holloway et al., 2008). Nevertheless, there is 
world-wide consensus that carrier women should be tested for cardiac disease.
Symptoms in female carriers could be explained by non-random X-inactivation where the 
normal X-chromosome is preferentially inactivated (Azofeifa et al., 1995). It was suggested 
that it is useful to study the pattern of X-inactivation in carriers of DMD because women 
with skewed X-inactivation may show slower, yet progressive, myopathy with advancing 
age (Yoshioka et al., 1998). Sumita et al. have shown that a high proportion of asymptomatic 
carrier women (19%, 19/102) as well as normal female controls (24%, 28/117) show skewed 
inactivation in DNA isolated from lymphocytes (Sumita et al., 1998). They suggest that 
highly skewed X-inactivation pattern in blood is not enough to predict that a young DMD 
carrier will develop muscular weakness. X-inactivation was recently studied in 15 carriers 
with symptoms of DMD. Eight had exonic deletions or duplications, six had small mutations 
and one patient had two mutations. The X-inactivation result from one patient with a deletion 
was uninformative. Four of the seven with a deletion or duplication and one of the six with 
a small mutation showed skewed inactivation. All the rest showed a random pattern of X-
inactivation. The significance of these findings depends on the definition of skewed (a value 
that is larger than 80:20). The authors concluded that they were not able to demonstrate a 
significant association between the X-inactivation pattern and progressive myopathy and that 
future studies with a larger number of subjects are required (Soltanzadeh et al., 2010). 
1.2.2  Female dystrophinopathy patients 
The following mechanisms that explain the phenotype of females with full blown 




• Women with translocations involving an X-chromosome with the breakpoint in Xp21 
and an autosome show preferential inactivation of the normal X with the normal DMD 
allele (Greenstein et al., 1980; Jacobs et al., 1981; Lindenbaum et al., 1979; Verellen-
Dumoulin et al., 1984; Zatz et al., 1981; Boyd et al., 1986). 
• A mutation in the DMD gene in the only X-chromosome of girls with Turner syndrome 
results in a phenotype similar to that of affected males (Chelly et al., 1986; Ferrier et al., 
1965; Sano et al., 1987). 
• Uniparental disomy for the X-chromosome with a mutation in the DMD gene has been 
described once (Quan et al., 1997). 
• Women with a 46,XY karyotype and DMD caused by the co-occurrence of mutations in 
both the dystrophin and the androgen-receptor genes have been described (Katayama et 
al., 2006). 
• Finally, two women have been described with a normal karyotype and mutations in 
both DMD genes. One, a 14 year old girl with consanguineous parents, is homozygous 
for the mutation (Fujii et al., 2009). The other is a 15 year old girl with compound 
heterozygous mutations. DNA analysis of the mother was normal and DNA analysis of 
the phenotypically normal father was not possible (Soltanzadeh et al., 2010). 
1.3  Diagnosing dystrophinopathies 
In the absence of a family history, DMD may be suspected in a boy if he is not walking at the 
age of 16-18 months or if there is an unexplained increase in transaminases and certainly if 
he has a positive Gower’s sign. If there is a positive family history, any suspicion of abnormal 
muscle function should lead to a diagnostic investigation (Bushby et al., 2010a). The 
flowchart in Figure 2 shows how the diagnosis of DMD can be confirmed. In the Netherlands, 
blood from almost all boys with a suspicion of dystrophinopathy is sent to the Laboratory of 
Diagnostic Genome Analysis at the Leiden University Medical Center. If a mutation is found 
in the DMD gene the clinical diagnosis is confirmed. If no deletion or duplication (MLPA 
test) is found and dystrophin in the muscle biopsy is absent, High Resolution Melting Curve 
Analysis (HR-MCA) is done followed by sequencing of the amplicons with abnormal melting 
curves (Almomani et al., 2009). cDNA sequencing (obtained from RNA) is performed in 
rare cases where the above mentioned tests have not revealed a DNA mutation. Once the 
diagnosis has been confirmed, referral to a specialized multidisciplinary team as well as 
genetic counselling of the patient and his family members is recommended. The patient and 






Confirmation of diagnosis in a patient suspected of having Duchenne muscular dystrophy. 
DMD is suspected when serum CK is increased by at least 10 times the normal value. It is recommended 
to start with MLPA analysis of DNA from blood because this is easy to obtain and in about 60% of 
the patients a deletion or duplication is found. Some physicians start with a muscle biopsy. *Absence 
of dystrophin in the muscle biopsy is in principle enough to confirm the diagnosis. However, genetic 
testing to detect a mutation is a part of standard care in the Netherlands since this is indispensable for 
reliable carrier testing of the mother and if applicable of other female family members. Also, with the 
development of personalized medicine the mutation should be identified. In rare cases, genetic testing 
does not reveal a mutation even though dystrophin is absent in the muscle biopsy. If the diagnosis of 
dystrophinopathy is not confirmed by either the muscle biopsy or by genetic testing, the diagnosis 
of alternative muscular dystrophies, which is complex and requires specialized input, should be 




In patients suspected of dystrophinopathy a muscle biopsy should be taken if genetic testing 
does not reveal a deletion or duplication. If it is BMD, immunohistochemistry of the muscle 
tissue may show reduced intensity with or without patchy staining (Hoffman et al., 1988). 
Western blot analysis should also be performed and if this shows an abnormal molecular 
weight and/or reduced quantity of the dystrophin, BMD is highly likely. In that case HR-MCA 
should be carried out. Less common dystrophinopathies may be suspected in the absence of 
a mutation but the presence of hyperCKemia and other symptoms such as cramps, myalgia, 
flexion contractures of elbows, wheelchair dependency after the age of 16, unexplained dilated 
cardiomyopathy and/or an X-linked family history with similarly affected family members. 
According to recent guidelines proposed for patients with unexplained hyperCKemia, a 
muscle biopsy should be taken if one or more of the following features are present: the level 
of serum CK is ≥3 times normal, the electromyogram is myopathic or the patient is younger 
than 25. In addition, DNA testing should be offered to women even if the level of serum 
CK<3 times normal. This should be done prior to a muscle biopsy because of the possibility 
that there is a mutation in the dystrophin gene (Kyriakides et al., 2010). As the symptoms are 
sometimes very mild it is possible that many patients with dystrophinopathy do not consult a 
doctor and are therefore not diagnosed. 
1.4  Genetic counselling and prenatal testing 
The family is referred for genetic counselling following the identification of a mutation in 
the index patient. The family members are informed that the dystrophinopathy could have 
occurred as the result of a de novo mutation or that the disease may have been inherited from the 
mother. In case of a de novo mutation the mother should be offered prenatal testing in the next 
pregnancy because of the risk of germ line mosaicism (see Section 1.5 below). The sisters of 
the patient may also request molecular testing of the familial mutation. If the dystrophinopathy 
is found to be inherited, further testing of first degree female family members of the mother by 
cascade screening is recommended. Options for having healthy offspring should be discussed 
with the identified carriers and cardiological surveillance should be offered (see Section 1.2: 
Dystrophinopathy in women). 
It has been recommended that prenatal diagnosis for dystrophinopathies should be carried 
out only for male pregnancies. At present, it is not possible to predict whether a female 
heterozygote for a DMD mutation will manifest any signs of the disorder or not, and it is, 
therefore, considered to be inappropriate to offer prenatal testing for a female foetus (Abbs 
et al., 2010). The sex of the foetus can be determined by examining the foetal cells in the 
maternal serum (Lo et al., 1997). Prenatal testing for dystrophinopathy is usually performed 
in the 11th week of the pregnancy. A sample of chorionic villi from the developing placenta is 
taken either by means of a needle inserted through the abdomen of the woman or via a tube 
inserted through the vagina and cervix. The cells of the chorionic villi have the same genetic 
information as the foetus and can be used in a male foetus to test if the familial mutation has 





Most DMD patients inherit an X-chromosome with the mutation, which is present in all 
cells. One in three patients has DMD as a result of a de novo mutation (Haldane, 1935). If 
a new mutation occurs during meiosis in one of the parents, the egg or the sperm will carry 
the mutation and will pass it on to the child who will have the mutation in all cells. If, on the 
other hand, a new mutation occurs during mitosis in the embryo a proportion of somatic and/
or germ line cells, will carry the mutation. Such a person is a mosaic with a mixture of cells, 
some with and some without the mutation (Erickson, 2010). Mosaicism refers to the presence 
of two (or more) cell lines with different genotypes in one individual who has developed 
from a single fertilized egg. Somatic mosaicism has been described in several patients with 
dystrophinopathy (Bakker et al., 1989; Bunyan et al., 1994; Bunyan et al., 1995; Helderman-
van den Enden et al., 2003; Lebo et al., 1990; Saito et al., 1995; Smith et al., 1999; van Essen 
et al., 2003; Voit et al., 1992; Kesari et al., 2009; Rajakulendran et al., 2010; Uchino et al., 
1995). A mutation can also occur in a germ line cell in the gonad, in which case mosaicism 
is confined to the germ cells and a proportion of eggs or sperm carry the mutation. Such a 
person with germ line mosaicism, also called gonadal mosaicism, does not have the disease 
but can pass on the mutation to more than one child. Germ line mosaicism was reported in a 
number of families with dystrophinopathy in the late 80s (Bakker et al., 1987; Bech-Hansen 
et al., 1987; Darras and Francke, 1987). The recurrence risk due to germ line mosaicism for 
non-carrier females was estimated to be 7% (Bakker et al., 1989) and 10% (van Essen et 
al., 1992a). A recent and more reliable figure, as it is based on many more families, is 4.3% 
(Chapter 2.1 of this thesis) (Helderman-van den Enden AT et al., 2009).
1.6  Genetics and proteomics of the dystrophinopathies
1.6.1  The DMD gene 
The inheritance of the dystrophinopathies is X-linked recessive. In 1983 Duchenne muscular 
dystrophy was found to be linked to two markers on the short arm of the X-chromosome 
(Davies et al., 1983). Subsequently the DMD gene was mapped on band Xp21 in 1985 (Ray 
et al., 1985) and cloned in 1987 (Koenig et al., 1987). With a size of ~2.4 Mb, it is the largest 
known human gene (den Dunnen et al., 1992). The DMD gene occupies about 1/1000 of the 
total human genome (Koenig et al., 1987). It has 79 exons which account for only 0.6% of 
the gene. The remaining part consists of large introns (Aartsma-Rus et al., 2006). The gene 
has seven promoters: three of them, the brain, muscle and Purkinje promoters, lead to a full 
length dystrophin which consists of unique first exons spliced to a common set of 78 exons 
(Sadoulet-Puccio and Kunkel, 1996). The size of the mRNA in the muscle is 14 kb. Four 
promoters (retina, brain3, schwann cells and general) lead to shorter dystrophin proteins 
which lack the actin binding terminus but retain the cystein rich and carboxy-terminus 
domains (Muntoni et al., 2003). The different promoters are named after the predominant, 
but not exclusive, site of expression as can be seen in Table 1.
18
Introduction
1.6.2  Mutation types in the DMD gene
Mutations reported in the Leiden DMD mutation database (www.dmd.nl) include deletions 
(72%) and duplications (7%) of one or more exons; the remaining ~ 20% of the patients have 
small deletions, insertions or point mutations (Aartsma-Rus et al., 2006). 
In 1988 it was postulated that DNA mutations that disrupt the reading frame result in DMD 
while mutations that maintain the reading frame result in BMD (Malhotra et al., 1988; 
Monaco et al., 1988). The disrupted reading frame generates an out-of-frame messenger 
RNA transcript that results in a premature truncation of translation. The truncated protein 
that is formed lacks the cystein rich and C-terminal domains and has no or little bridge 
function. In BMD the reading frame remains intact; the protein is partly functional and its 
presence can be demonstrated in the muscles of the patients. In the more than 4700 mutations 
reported in the DMD gene in the Leiden DMD database, the reading-frame rule holds true 
at the DNA level in 91% of the patients; at the RNA level this percentage probably goes up 
to 99.5% (Aartsma-Rus et al., 2006). Non-sense mutations normally result in DMD because 
of the premature stop in protein translation. In rare cases a non-sense mutation is found in a 
BMD patient. The most likely explanation for the unexpected non-DMD phenotype is that 
the mutation is located in the exonic motive that is needed for the recognition of the exon by 
Isoform
Symbol   
Isoform Name   Location of 
promoter/unique 




Tissue Expression Pattern   Reference  
Dp427c   Brain/Cortical- 
dystrophin   
5’ of Dp427m   427 kDa   Cortical neurones, skeletal and 
cardiac muscle  




dystrophin   
5’ of Dp427m 
exon 1
427 kDa   Skeletal and cardiac muscle and 
glial cells




Dp427p   Purkinje-
dystrophin   
Dp427m intron1  427 kDa   Purkinje cerebellar neurons  




Dp260   Retinal 
dystrophin   
intron 29   260 kDa   High in retina  





Dp140   B3-dystrophin   intron 44   140 kDa   Brain, retina and kidney   (Lidov et 
al., 1995)
Dp116   Schwann cell-
dystrophin   
intron 55   116 kDa   Peripheral nerves (Schwann cells) 
exclusively   
(Byers et 
al., 1993)
Dp71   General-
dystrophin   
intron 62    71 kDa   In most tissues – brain, kidney, liver, 
lung, cardiac muscle  




Overview of the tissue expression of the different isoforms of dystrophin (with the kind permission of 




the splicing machinery, and thus leads to exon skipping resulting in a restored reading frame 
(Flanigan et al., 2010; Ginjaar et al., 2000). 
1.6.3 Dystrophin protein
Dystrophin is the protein encoded by the DMD gene; its molecular weight is 427 kDa and 
the number of amino acid (AA) residues, as deduced from the nucleotide sequence, is 3,685 
(Hoffman et al., 1987). The dystrophin protein is absent in most muscle fibers of DMD patients. 
In about 50% of the DMD patients there may be some dystrophin positive fibers. The most likely 
explanation of these so-called revertant fibers is spontaneous in-frame splicing, for example 
after a second mutation (Klein et al., 1992; Mendell et al., 2010). 
The full length muscle dystrophin is composed of the following four domains (Figure 3):
• The actin-binding domain is so called because the N-terminal portion is highly 
homologous to the N-terminal portion of α-actinin. It consists of between 232 and 240 
amino acids, depending on the isoform, and has three actin binding sites (Jarrett and 
Foster, 1995; Koenig et al., 1987; Koenig and Kunkel, 1990).
• The central rod domain is the largest part of the protein and is composed of approximately 
3000 amino acids. It is formed by a succession of 24 triple helical repeats similar to 
spectrin. In addition, and in contrast to the spectrin molecules, four predicted hinges 
separate the rod region into three sub-regions which are thought to impart flexibility to 
the protein (Koenig and Kunkel, 1990). A fourth actin-binding site was found between the 
spectrin-like repeat units 11-17 (Amann et al., 1998; Rybakova et al., 1996). The multiple 
spectrin-like repeats had long been thought to be largely redundant because patients with 
a missing part in the central rod usually had only mild symptoms (England et al., 1990). 
However, recent studies have shown that the spectrin-like repeats harbour sites that bind to 
membrane phospholipids, intermediate filaments, microtubules and neuronal nitric oxide 
synthase. This suggests that the central rod domain is more of a scaffolding region, rather 
than simply a passive link between the N-and C-terminal ends (Lai et al., 2009; Le et al., 
2010).
• The cystein-rich domain has 15 cysteine residues and consists of 280 amino acids 
(Koenig et al., 1988). This part of the protein interacts with β-dystroglycan and has 
the following components: the WW domain, two EF hands and ZZ domains. The WW 
domain contains two conserved tryptophan (W) residues 20-23 amino-acids apart (Bork 
and Sudol, 1994) and is the primary site of interaction between dystrophin and the last 
15 C-terminal amino acids of β-dystroglycan (James et al., 2000; Jung et al., 1995). The 
EF hands are putative calcium-binding sites that stabilize the WW domain and have 
affinity for β-dystroglycan (Chung and Campanelli, 1999; Huang et al., 2000). Finally, 
the ZZ domains are highly conserved widespread zinc-binding motifs that stabilize the 
overall complex by interacting with β-dystroglycan (James et al., 2000; Rentschler et 
al., 1999). The part of the ZZ domain formed by the amino acids 3326-3332, is crucial 
for binding to the β-dystroglycan (Hnia et al., 2007).
• The C-terminal domain consists of 420 highly conserved amino acids, with only one 
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cystein residue. It forms an α-helical dimeric coiled-coil structure that interacts with 
syntrophin (Ahn and Kunkel, 1995; Koenig et al., 1988) and dystrobrevin (Sadoulet-
Puccio et al., 1997). 
 
As mentioned above more isoforms are known in addition to the muscle dystrophin. The 
eight dystrophin isoforms and utrophin, a homologue of dystrophin, are depicted in Figure 
4; the uppermost is the muscle isoform. The full-length dystrophins Dp427m, Dp427c and 
Dp427p consist of N-terminal, central rod, cysteine-rich and C-terminal domains, but each 
isoform has its own unique N-terminal part (which is coded by a unique first exon, depicted 
with  ). The shorter isoforms lack some, or most of the N-terminal and/or central rod domains, 
and also have their own unique first exon (except for Dp140). Dp71 is usually alternatively 
spliced, which gives rise to an alternative C-terminal part. Dp40 derives from an alternative 
poly-adenylation signal in intron 70. The dystrophin homologue utrophin is very similar to 
the full-length dystrophin isoforms.
Figure 3
Schematic drawing of the dystrophin protein adapted from (Aartsma-Rus et al., 2006). The location of 





Schematic drawing of 
the different dystrophin 
isoforms and homologues 
(Aartsma-Rus, 2005) (with 
the kind permission of 
Aartsma-Rus). 
Figure 5 
The dystrophin glycoprotein complex as it is located in the sarcolemma, the cell membrane of 
the muscle cell (with the kind permission © QIAGEN, all rights reserved).
1.6.4  Dystrophin and the dystrophin glycoprotein complex 
Dystrophin is part of the dystrophin glycoprotein complex. This complex consists of the 
cytoplasmic dystrophin-containing complex, the dystroglycan complex, the sarcoglycan 
complex and the sarcospan as can be seen in Figure 5.
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Dystroglycan is composed of 2 subunits, α and ß, both produced from the same gene. 
Dystrophin binds to the tail of ß-dystroglycan. Dystroglycan binds to the extracellular matrix 
laminin-α2. The sarcoglycan complex is composed of multiple subunits. Mutations in the 
genes encoding α-, ß-, γ-, and δ-sarcoglycan lead to a phenotype similar to the one produced 
by mutations in the DMD gene and include cardiomyopathy and muscular dystrophy in 
humans and mice (Lapidos et al., 2004).
The dystrophin glycoprotein complex forms a mechanically strong link between the 
sarcolemma and actin (Rybakova et al., 2000). The muscle isoform of dystrophin serves 
as bolts throughout the sarcolemma stitching the sarcolemma with the intracellular actin 
filaments. The dystrophin bolts are more densely located at the costameres. A costamere is 
a protein complex located at the Z disc of the sarcomere and forms the transverse fixation 
system (TFS) of the intracellular desmin-vimentin intermediate filaments (DVIF) with the 
basal lamina (Figure 6). These dystrophin bolts protect the lipid bilayer from injury which 
might occur upon contraction of the muscle (Ozawa, 2010). The fact that no symptoms are 
present at birth in dystrophinopathy patients can be explained by the presence of utrophin, 
a protein with a function similar to that of dystrophin. The less densely distributed utrophin 
bolts appear first in the myotube stage and are later replaced by dystrophin bolts. Only when 
the patient starts to walk the utrophin bolts appear to be insufficiently strong to bear the 
muscle contractions and the lipid bilayer gets damaged (microtears) leading to a gradual 
atrophy and weakness of the muscle (Ozawa, 2010). Atrophy results from, on the one hand, 
leakage of soluble cytoplasmic enzymes and other proteins through the microtears and, on the 
other hand, from increased digestion of proteins through activated calpain due to leakage of 
Ca++ into the cytoplasm (Imahori, 1980). However, it is not known why only DMD muscles 
athrophy whereas also healthy muscles contain calpain and free Ca++ waxes and wanes 
during the contraction-relaxation cycle of the muscle (Ozawa, 2010). 
 
Figure 6
Transverse fixation system (TFS) (Ozawa, 2010). Adapted with kind permission of Professor E. 
Ozawa.
Desmin Vimentin Intermediate Filaments (DVIF) are wound around myofibrils (mf) at the level of the 
Z-band and connected with actin in the subsarcolemmal cytoskeleton. The small vertical bars below the 




1.7  Therapy 
Therapy for DMD and BMD is at present only symptomatic and should be administered by a 
multidisciplinary team (Bushby et al., 2010a; Bushby et al., 2010b). For optimal management, 
care is recommended in the following areas: pharmacology, psychosocial, rehabilitation, 
orthopedic, respiratory, cardiovascular, gastroenterology/nutrition, pain issues and general 
surgical and emergency-room precautions. The life expectancy has increased from 14.4 years 
in the 1960s to 25.3 in the 1990s just by treating the symptoms (Eagle et al., 2002). Some 
patients even reach the age of 40 or older (Rahbek et al., 2005).
Experimental therapy with the aim of restoring the absent dystrophin in the muscle has 
recently been focused on two treatments: antisense-mediated exon skipping and drug-induced 
read-through of premature stop codons (Aartsma-Rus et al., 2010). Both treatments fall under 
so-called personalized medicine because they depend on the specific mutation. The exon 
skipping treatments seem particularly promising (Goemans et al., 2011; Van Deutekom et al., 
2007); a phase III trial with skipping of exon 51 has been recently started and includes 180 
patients from 18 different countries (http://www.gsk.com/media/pressreleases/2011/2011_
pressrelease_10016.htm). Exon skipping treatment is based on manipulating the splicing 
machinery with antisense oligonucleotides (AON) in a manner that one or more exons are 
skipped with the aim of restoring the reading frame, finally resulting in the production of 
BMD-like dystrophin and a milder phenotype (Figure 7). 
Figure 7 
Exon skipping treatment (adapted with the kind permission from www.dmd.nl/gt).
An out-of-frame product is generated in which exon 47 is spliced to exon 51 in a patient with DMD 
with a deletion of exons 48-50. As a result, a stop codon is generated in exon 51, which prematurely 
aborts dystrophin synthesis. The sequence-specific binding of the antisense oligonucleotide PRO051 
interferes with the correct inclusion of exon 51 during splicing so that the exon is actually skipped. This 
restores the open reading frame of the transcript and allows the synthesis of dystrophin similar to that 
in BMD patients (Van Deutekom et al., 2007).
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The other treatment, the drug-induced read-through of premature stop codons is based on 
the finding that certain antibiotics (aminoglycosides) suppress stop codons during protein 
translation. In 1999 dystrophin was shown to appear at the cell membrane in mdx myotubes 
after in vitro exposure to gentamycin (Barton-Davis et al., 1999). A decade of further testing 
followed until recently when a phase 2B study during 48 weeks with Ataluren (formerly 
known as PTC124) was completed in 174 DMD patients. There was no measurable difference 
between the effect of a high dose of Ataluren and a placebo in the 6-min walk test; also the 
effect of a low dose of Ataluren as compared to the placebo was not significant. These results 
have led to a suspension of further trials http://www.duchenne.nl/976_resultsataluren.pdf. 
1.8  Aims of this thesis
The focus of this thesis is on the clinical genetic aspects of dystrophinopathies. 
We have investigated the following topics:
Mosaicism:
Germ line mosaicism was described by several authors in the late 80s (Bakker et al., 1987; 
Bech-Hansen et al., 1987; Darras and Francke, 1987). Since then the number of families in 
which this phenomenon has been encountered in Leiden, has increased. We were therefore 
able to calculate a more reliable figure for the recurrence risk (Chapter 2.1). We performed this 
study also because it was suggested that the published recurrence risks may be overestimates 
(Castagni et al., 2004). 
A reliable recurrence risk is important for genetic counselling of women who have a son with 
dystrophinopathy as a result of a de novo mutation. As a part of this study we reviewed the 
literature on other known diseases with germ line mosaicism. 
If a de novo mutation occurs in the DMD gene in one of the later divisions of the zygote, it 
can result in mosaicism in somatic tissues as well as in the germ line. Chapter 2.2 describes 
a male patient with somatic mosaicism. 
Cascade screening in known families with dystrophinopathy 
The study presented in Chapter 3 was prompted by the fact that women from several DMD 
families appeared to be unaware of their risk of being a carrier and had given birth to an 
affected boy. In this chapter we examine whether females at risk for being a carrier of a DMD 
mutation have been tested and counseled after the causative mutation was identified in an 
index case. Since DMD is a devastating disease for which there is no curative therapy so far, 
much emphasis has been put on prevention. Prevention is only possible if women are aware 
of this disease in their family. These women need to be informed about their risk of being a 
carrier, the recurrence risks, their reproductive options, the available tests and the health risks 
for carriers.
What has been the impact of prenatal testing for Duchenne and Becker Muscular 
Dystrophy in the Netherlands?




since 1984 (Bakker et al., 1985). In Chapter 4 we show the impact of genetic counselling, 
the use of prenatal testing and pre-implantation genetic diagnosis on the occurrence of DMD 
and BMD in the Netherlands. The incidence of DMD in the birth cohort 1993-2002 was 
compared with the incidence in the birth cohort 1961-1974 (van Essen et al., 1992b). In order 
to test effectiveness of genetic studies in DMD families with regard to preventing the birth 
of affected boys we have also compared the proportion of first affected boys in the family 
between the two cohorts. A need for a change in policy has emerged.
Predicting the phenotype of DMD patients who have been treated with exon skipping 
therapy
Currently, new therapeutic strategies, such as antisense-mediated exon skipping, are in an 
early phase of clinical trials and have the potential of dramatically changing the course of 
the DMD disease (Goemans et al., 2011; Van Deutekom et al., 2007). Clinical trials with 
systemic administration of antisense oligonucleotides (AON) are taking place. If successful, 
therapeutic skipping using an AON that targets exon 51 can stop further muscle wasting, 
resulting in a less severe clinical phenotype resembling BMD. It is, therefore, useful to study 
the phenotype of BMD patients as it can provide information for DMD patients eligible for 
this new therapy. In Chapter 5 we have described the clinical phenotype in two Dutch BMD 
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The presence of multiple affected offspring from apparently non-carrier
parents is caused by germ line mosaicism. Although germ line mosaicism
has been reported for many diseases, figures for recurrence risks are
known for only a few of them. In X-linked Duchenne and Becker
muscular dystrophies (DMD/BMD), the recurrence risk for non-carrier
females due to germ line mosaicism has been estimated to be between
14% and 20% (95% confidence interval 3–30) if the risk haplotype is
transmitted. In this study, we have analyzed 318 DMD/BMD cases in
which the detected mutation was de novo with the aim of obtaining
a better estimate of the �true’ number of germ line mosaics and a more
precise recurrence risk. This knowledge is essential for genetic counseling.
Our data indicate a recurrence risk of 8.6% (4.8–12.2) if the risk
haplotype is transmitted, but there is a remarkable difference between
proximal (15.6%) (4.1–27.0) and distal (6.4%) (2.1–10.6) deletions.
Overall, most mutations originated in the female. Deletions occur more
often on the X chromosome of the maternal grandmother, whereas point
mutations occur on the X chromosome of the maternal grandfather. In
unhaplotyped de novo DMD/BMD families, the risk of recurrence of the
mutation is 4.3%.
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A genetic disease in a child with healthy non-
carrier parents is usually a result of a de novo
mutation that has taken place during cell division
(mitosis/meiosis). The mutation rate for most
genetic diseases is low, and hence, the risk of a
second mutation in the same gene in a specific
family is negligibly small. If the mutation occurs
during mitosis, a large number of cells (germ
and/or somatic) may carry the mutation, thus
increasing the risk for a second affected child.
The presence of multiple affected offspring from
apparently non-carrier parents is due to germ line
mosaicism. So far, germ line mosaicism has been
reported for more than 60 genetic diseases. Recur-
rence risk is known for only a few of these.
Duchenne muscular dystrophy (DMD) is a lethal
X-linked recessive disorder and is caused by muta-
tions in the dystrophin gene. Mutations in this gene
canalso lead toBeckermuscular dystrophy (BMD).
An affected boy usually inherits the dystrophin
gene mutation from his mother. The carrier
mother has a 25% risk of having a second affected
child in each pregnancy.
In 1935, Haldane (1) postulated that for X-
linked lethal recessive disorders like DMD, one
in three patients has the disease as a result of
a de novo mutation.
If one in three DMD patients is affected as a
result of a newmutation, then one in threemothers
is not a carrier. One would expect that in these
cases, the risk for a subsequent pregnancy would
be zero. However, this is not the case.
Germ line mosaicism in DMD was described by
several authors in the late 80s (2–4). The estimate
of the recurrence risk for non-carrier females due
to germ line mosaicism of transmitting the risk
haplotype varies between 14% (95% confidence






meeting of the European Society of Human
Genetics in 2004, Castagni et al. presented a poster
on germ line mosaicism in a group of 273 Italian
families. There were only two cases where the
de novo mutation in the dystrophin gene was
transmitted twice, suggesting that previous studies
may have overestimated the recurrence risk (7).
In this study, we have analyzed our proven
de novoDMD/BMD cases with the aim of obtain-
ing a better estimate of the �true’ number of germ
line mosaics and to assess the resulting recurrence
risk more precisely, which is essential in genetic
counseling. The recurrence risks are specified with
respect to the type of the mutation and its location
within the gene.
We have also traced the origin of the mutation
(maternal, maternal grandmother or maternal
grandfather) by haplotype analysis of de novo
families and have investigated whether there is
a relationship between the type of mutation and
its origin.
Methods
Since the availability of DNA diagnostics in 1984,
more than 1500DMD/BMDpatients/families have
been tested in our laboratory. Mutations in most
families are known and their DNAhas been stored.
The records of the patients/families were
selected on the basis of a mutation detected in
the dystrophin gene that was proven to have
arisen de novo. A family was considered to have
a de novomutation if themother of the patient or if
the parents of a carrier mother did not have the
mutation in their lymphocytes.
The risk haplotype was determined in the
selected de novo families. We then examined the
frequency of the risk haplotype transmission with
or without the mutation.
In a number of healthy siblings, either haplotyp-
ing was not informative (sisters without the muta-
tion) or DNA was unavailable (healthy brothers).
Yet these siblings provide valuable information
about the recurrence risk. By using Bayes’ theo-
rem as described in the supplementary materials
available as part of the online article at http://
www.blackwell-synergy.com, we were able to
compute the expected number of siblings assumed
to have the risk haplotype without the mutation.
In a number of families where themutationmust
have occurred in one of the grandparents, it was
not possible to establish its origin. This was usu-
ally due to the non-availability of DNA of the
grandfather. The probability of the origin, and
hence the number of transmitted risk haplotypes,
depends on F, the number of haplotyped siblings
and the number of healthy siblings with no infor-
mation about the haplotype. In the supplementary
materials available as part of the online article at




in our laboratory, 318 families were identified with
proven de novomutations, 272 families with DMD
and 46 families with BMD.
Part A: Recurrence risk due to germ line mosaicism
The mutation was transmitted more than once in
19 cases. Table 1 gives an overview of the families
with germ line mosaicism and the detected
mutations.
The risk haplotype without a mutation was
transmitted 108 times (data not shown) to a
healthy sibling. No information about the haplo-
type was available from 176 healthy siblings. The
a priori risk that these 176 siblings received the
risk haplotype is 50% (88). By using the algorithm
described in the supplementary materials, 84 sib-
lings without haplotype information could be
added to the 108 siblings with the risk haplotype.
































aEighteen families are shown, whereas we counted 19 cases
of germ line mosaicism. In family BL138, the de novo
mutation was transmitted three times. The exon numbers of
the deletion family DL114 could not be further specified
because there was insufficient DNA and no new material was
available.





From the families with unknown grandparental
origin, we estimated that another 11 siblings are
likely to carry the risk haplotype.
In total, the number of siblings with the risk
haplotype is therefore 203 (108 1 84 1 11).
The recurrence risk if the risk haplotype is trans-
mitted is:
19=ð203119Þ ¼ 0:086ð ¼ 8:6%Þ
ð95% confidence interval :4:8212:2Þ:
Table 2 gives an overview of the origin and the
type ofmutation. Themost frequent type ofmuta-
tion, a deletion, was present in 246/318 families.
The deletions are subdivided as proximal, middle
and distal to be able to calculate the specific recur-
rence risks for these types of deletions.
Figure 1 shows two hot spots of deletions; most
deletions are found in the distal hot spot. The
graph in Fig. 2 shows the distribution of deleted
exons in families with proven germ line mosaicism
due to a deletion. Both hot spots can be seen.
However, the distal hot spot is significantly lower
compared with the distal hot spot in the entire
group of de novo deletions (Fig. 1). Table 1 shows
the families with proven germ line mosaicism: six
deletions proximal and eight distal. Table 2 shows
the whole group of de novo deletion families: 53
proximal vs 182 distal.
The recurrence risks for the different types of
mutations were calculated in the same manner as
described above for the entire group. Table 3
shows the results. No recurrence risk is calculated
for a middle deletion because the total number of
middle deletions was too small (11 families).
Part B: Origin of the new mutation
Table 2 shows that most families (77%) had
a deletion; duplications and point mutations were
found in 11% and 12%. In 232 families, the
mother was not a carrier; hence, the mutation
has arisen in the germ line of the mother. In 40
families, the mutation originated in the grand-
mother and in 27 families in the grandfather. In
19 families, the origin of themutation could not be
determined (see Methods).
Discussion
Recurrence risk due to germ line mosaicism
Hall in 1988 and Edwards in 1989 speculated that
every woman has several oocytes with mutations
for common genetic disorders because the 6–8mil-
lion oocytes exceed the denominator of the muta-
tion rates for these diseases (8, 9). In themale germ
line, an even greater range of mutations is ex-
pected to be present.
The result of a literature search on germ line
mosaicism is added as a supplement and can be
viewed online at http://www.blackwell-synergy.
com in the supplementary materials.
An estimate for the recurrence risk was found
for only 7 of 63 diseases: 2 with an autosomal
dominant and 5 with X-linked inheritance. The
recurrence risks vary as follows: 0.02% [achon-
droplasia (10)], 5–7% [autosomal dominant osteo-
genesis imperfecta (11)], 11% [RETT syndrome
(12), double cortex X-linked lissencephaly syn-
drome (13) and hemophilia B (14)] and 13%
[hemophilia A (15)].
In DMD, the reported recurrence risks vary
from negligible to 14–20% if the risk haplotype
is transmitted (5–7). For genetic counseling, it is
important to have a reliable estimate of the recur-
rence risk attributed to germ line mosaicism. Our
study describes the largest number of families with
a de novo mutation known to date, and we found
a recurrence risk, if the risk haplotype is transmit-
ted, of 8.6% (95% confidence interval 4.8–12.2).
In the current counseling practice, information
about the risk haplotype is usually not obtained
because only the presence/absence of themutation
is tested in the at-risk sibling. One should use
a recurrence risk of 4.3% in these families with
no information about the risk haplotype.
Table 2. Overview of the origin and type of mutationa
Type of mutation Maternal Maternal grandmother Maternal grandfather Unknown Total
All deletions 183 35 14 14 246 (77%)
Proximal deletion 35 10 6 2 53
Middle deletion 8 1 1 1 11
Distal deletion 140 24 7 11 182
Duplication 25 3 5 2 35 (11%)
Point mutation 24 2 8 3 37 (12%)
Total 232 (73%) 40 (13%) 27 (8%) 19 (6%) 318 (100%)
aA deletion is defined as proximal if most deleted exons are found in the proximal hot spot (exons 3–20) and as distal if most
deleted exons are distal to exon 40. The other deletions are located in the middle of the gene between exons 20 and 40.






Fig. 1. Overview of the found deletions. Graphic representation of the location of 245 deletions (the border of one deletion
could not be defined: DL114 del probe 30.1 because of insufficient DNA). The number of times that each individual exon is
deleted is shown on the y-axis, and the x-axis shows the different exons. The lines in the lower part represent individual
deletions. Summing of the individual deletions has resulted in the graph on the top.





This figure is remarkably close to the 4.5%
recurrence risk calculated by Van der Meulen
et al. in 1995 (16). The primordial germ cell divides
mitotically, so that in the ith generation of the
germ cells, there are 2i cells. If this process contin-
ues for a total of n cells (n may be different in
females and males), then at maturity, there are
2n germ cells. Hartl (17) showed that more com-
plex versions of this simple model do not change
recurrence risks as long as the number of gonadal
generations is high enough. The recurrence risk
due to germ line mosaicism can be calculated with
the following formula:
Recurrence risk ¼ +ni¼11=n:ð2Þ
2i � 1=n:
If the number of generations needed to form the
5–7 million oocytes is at least 22 in females (18),
the recurrence risk according to this formula is 1/22
� 0.045 ¼ 4.5%.
In the majority of the de novo families, the muta-
tion originated in the germ line of the mother
(in our study 232/318) or the maternal grand-
mother (40/318), whichmight explain the fact that
the theoretical calculated recurrence risk is close
to our empirical risk.
The mutations with proven germ line mutations
are deletions in 14/18 (77%), duplications in 3/18
(17%) and a point mutation in 1/18 (6%) families.
These percentages are divided as the expected
ratio of mutations in the dystrophin gene, apart
from the number of point mutations, which is
smaller than expected. This can be explained by
the fact that these type of mutations are more
difficult to locate.
Different mosaicism frequencies for proximal and
distal deletions
If the distribution of mutations in familial and
sporadic cases was identical, no difference
between these groups would be expected. Passos-
Bueno et al. observed that in familial cases of
DMD/BMD caused by a deletion, 47% of these
were found in the proximal hot spot and 53% in
the distal hot spot, whereas in sporadic cases, 28%
of the deletions were found to be proximal and
72% distal (19). Furthermore, they found that
germ line mosaicism for DMD was present more
Fig. 2. Distribution of the deleted exons in 13 families with a de novo deletion and proven germ line mosaicism. Not included
in this figure is family DL114 with a deletion of probe 30.1, this is also a proximally located deletion. The boundaries of the
deletion could not be defined, however, because of insufficient DNA.
Table 3. Recurrence risk due to germ line mosaicism
Type of mutation
Recurrence risk (%)







All types together 8.6 (4.8–12.2) 4.3
All deletions 8.4 (4.2–12.6) 4.2
Proximal deletion 15.6 (4.1–27.0) 7.8
Distal deletion 6.4 (2.1–10.6) 3.2
Duplication 12.1 (1.0–23.2) 6.1
Point mutation 4.4 (0–12.7) 2.2






often in the proximal hot spot than in the distal
one. These authors calculated different mosaicism
frequencies for proximal and distal DMD muta-
tions. A distinct recurrence risk of 30%was found
for proximal de novomutations and 4% for distal
mutations. It was speculated that proximal dele-
tions arise earlier in embyrogenesis than distal
ones. This explains the higher recurrence risk
because more cells would carry the mutation.
The present study confirms a difference between
the recurrence risk for germ line mosaicism for
proximal and distal deletions. The difference,
however, is much smaller: a proximal deletion
has a risk of recurrence of 15.6% whereas a distal
deletion has 6.4%. Of the three families with germ
line mosaicism caused by duplications, two
involved also the proximal part of the gene, but
it is known that duplications are foundmore often
proximal than distal (20).
In our study, the recurrence risk due to germ line
mosaicism was 12.1% for duplications and 4.4%
for point mutations. These recurrence risks have
relatively large 95% confidence intervals due to
the small number of families in which duplications
(35/318) and point mutations (37/318) were
found.
We have added a flowchart (Fig. 3) for use in
estimating the recurrence risk in a family with
a sporadicDMDpatient. To our knowledge, these
recurrence risks are the most accurate at present,
and this flowchart should facilitate genetic coun-
seling. However, all 95% confidence intervals
overlap, and therefore, the recurrence risks for
the specific types ofmutations should be usedwith
caution.
Origin of the mutation
Since the description of the male to female ratio of
mutations by Haldane in 1947 (21), many articles
have been written on this subject. Usually, the
ratio in DMD is assumed to be 1, which makes
the risk of the mother being a carrier 2/3.
This variation of the male to female ratio of
mutations depending on the type of the mutation
has been described also for other diseases, for
instance, in X-linked hemophilia B (22).
In 86 of the 318 DMD/BMD families (27%) in
our study, the mutation arose in the grandparen-
tal germ line. This low percentage is not surprising
because an unknown number of women carrying
a de novo mutation in the dystrophin gene are
Sporadic DMD patient
DNA analysis in blood
No mutation Mutation identified
Immunohistochemical staining
of muscle biopsy for dystrophin 
Mutation present in mother?
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of) dystrophin gene (and


















Risk* 8 % Risk* 3% Risk* 6% Risk*  2%
Fig. 3. Flowchart for use in counsel-
ing for the recurrence risk in a family
with a sporadic Duchenne muscular
dystrophy (DMD) patient. Risk* is
the risk of an affected son if there is no
information about the haplotype.
Haplotype analysis is usually not
performed because now it is possible
to test for the mutation directly. The
recurrence risks for the specific types
of mutations should be used with
caution because, as can be seen in
Table 3, all 95% confidence intervals
overlap.





missed if they do not pass the mutation on to
a son.
Our study confirms that deletions in the dystro-
phin gene occur more often on the X chromosome
of the maternal grandmother (35 times) than of
the maternal grandfather (14 times). In a study
of 81 de novo DMD/BMD families in 1992 (6), it
was found that themutation came from the grand-
mother in 49 families and from the grandfather in
32 families. The authors concluded that the muta-
tion rate in males and females in their study did
not significantly deviate from an equal mutation
rate in both sexes. This study involved 97.4% de-
letions and only 2.6% duplications. Our study
confirms this result.
Point mutations originated more often in the
maternal grandfather (eight times) compared with
the maternal grandmother (two times). It is in the
literature a well-known phenomenon that point
mutations arise more often in the male germ line.
This is explained by the way germ cells in the male
are formed. There are about 30 cell divisions
before puberty and 1 about every 23 days there-
after. For a 30-year-old male, the number of cell
divisions is 380 (23). In the female germ line, there
are about 22 cell divisions (18).
At present, the mutation can be identified, and
reliable testing of family members is feasible in
most DMD cases. Our data indicate that in a fam-
ily of a sporadic DMD patient with unknown
mutation, the risk for a second affected boy can
be as high as 8.6% if the risk haplotype is present
in a subsequent male fetus. If MyoD can modify
chorion villus cells in the sameway as it does fibro-
blasts (24), we may be able to test the ability of the
fetus to make dystrophin in vitro and thus be
informed whether the fetus is affected or healthy.
The couple faces a difficult decision whether to
continue the pregnancy or not in case the MyoD
technique fails or is not available. If they decide to
terminate the pregnancy, it is important to collect
muscle tissue from the fetus. Immunohistochemi-
cal staining of dystrophin should be performed on
this tissue (25). If dystrophin is absent, the risk
that the mother is a carrier is high (although germ
line mosaicism cannot be excluded as long as the
mutation is unknown) and the couple will know
that their fetus was affected. If, however, dystro-
phin is present, the fetus was not affected with
DMD. In any case, prenatal testing should be
offered in a future pregnancy as there is still
a recurrence risk because of possible germ line
mosaicism.
Germ line mosaicism remains an important pit-
fall that should be considered during the counsel-
ing of families with a de novomutation. The 8.6%
risk of recurrence of the mutation in the risk hap-
lotype in our large series of families indicates the
need for assessing the potential DMD carrier risk
for all female members of families with apparent
de novo cases.
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In a number of healthy siblings either 
haplotyping was not informative (sisters 
without the mutation) or DNA was 
unavailable (healthy brothers). Yet these 
siblings provide valuable information about 
the recurrence risk. Bayes theorem is used as 
described below in the box to compute the 
expected number of siblings assumed to have 
the risk-haplotype without the mutation. 
The probability that a healthy sibling has 
the risk-haplotype without the mutation 
is 
 
     
Where F denotes the chance that a germ 
line mutation is present in the risk-
haplotype and (1-F) is the chance that 
the risk-haplotype does not have the 
mutation
If F is small this probability equals ½.
The numerator gives the risk that the 
healthy sibling has the risk-haplotype 
without the mutation.
The denominator gives the possibilities 
of a healthy sibling: the numerator and 
the possibility of receiving the non risk-
haplotype (=1/2)
Now the unknown parameter F can be 
estimated by using an EM algorithm which 
computes, based on a current value of F, 
the expected total number of haplotypes 
transmitted (E step) and then using these total 
number, the value of F is updated (M step). 
The expected total number of haplotypes is 
given by
Here the last term represents the healthy 
siblings for whom either haplotype was not 
informative or DNA was not available.
Then a new value of F is obtained by
These steps are repeated until convergence 
has been obtained. By using the algorithm 
described above, we calculated that 84 of 
the 176 siblings without information about 
the haplotype, probably carried the risk 
haplotype (so a little less than the apriori risk 
of 50%).
These formulas hold for families with known 
origin of mutation. For 19 (out of 86) families 
the origin was unknown. Also these families 
contain information about F. To include these 
families in the procedure, we formulated the 
posterior probability of origin as function of 
F and the observed family data. 
Let NDC be the number of daughters 
carrying the mutation, NDH be the number 
of daughters carrying the healthy haplotype, 
NDU be the number of daughters without 
mutation and NSU be the number of sons 
without the mutation.
Then the probability of the family give the 
origin of mutation are given by






Prob(NDC, NDH, NDU, NSU | maternal 
origin)= (½F)NDC (½-½F)NDH (1-½F)NDU+NSU
Using Bayes theorem and the prior 
probabilities of maternal origin of ⅔ 
and of paternal origin of ⅓, the posterior 
probabilities of origin can be calculated for 
each family. 
Now given the origin, the number of 
transmitted haplotypes can be counted as 
before and the total number of transmitted 
haplotypes in these families is the weighted 
sum of the number under maternal origin 
and under paternal origin weighted with 
the corresponding posterior probabilities 
of origin. This total number of expected 
transmitted haplotypes in the family can 
be added to the expected total number of 
transmitted haplotypes given above.
In this way we estimated that in the families 
with unknown grandparental origin another 





The following table was published online as a supplementary file of the article of Helderman et al 
titled: Recurrence risk due to germ line mosaicism: Duchenne and Becker muscular dystrophy.
Overview of the literature on germ line mosaicism
Only those references were included where multiple affected offspring with a detected mutation 
had apparently non-carrier parents (no mutation in lymphocytes). The diseases are presented in al-
phabetical order, followed by the name of the gene, the type of inheritance and the reference(s).
AD = autosomal dominant, AR = autosomal recessive, X-L = X-linked
Disease Gene AD  AR  X-L reference
Achondrogenesis type II  COL2A1 1   (1)
Achondroplasia FGFR3 1   (2, 3, 4)
Albright hereditary osteodystrophy GNAS1 1   (5)
Amyloid polyneuropathy TTR 1   (6)
Androgen insensitivity syndrome AR   1 (7)
Angelman syndrome UBE3A 1   (8)
Apert syndrome FGFR2 1   (9)
Campomelic dysplasia  SOX9 1   (10)
Charcot-Marie-Tooth disease type 1 (CMT1) MPZ/P0 1   (11, 12)
CHARGE CHD7 1   (13)
Coffin-Lowry syndrome  RSK2   1 (14)
Craniofrontonasal syndrome (CFNS) EFNB1   1 (15)
CRASH L1CAM   1 (16)
Crouzon FGFR2 1   (17)
Danon disease LAMP-2   1 (18)
Diabetes permanent neonatal  KCNJ11 1   (19, 20)
Duchenne muscular dystrophy dystrophin   1 (21, 22, 23, 24,  
     25, 26, 27, 28,  
     29, 30, 31, 32,  
     33, 34)
EEC P63 1   (35)
Epidermolysis bullosa lethal junctional (Herlitz)  LAMB3  1  (36)
Epidermolysis bullosa mild dystrophic form  COL7A1 1   (37)
Epidermolysis bullosa simplex  Keratin 5 1   (38)
Epilepsy, severe myoclonic form of infancy SCN1A 1   (39, 40)
Fabry alpha-gal A   1 (41)
Facioscapulohumeral myopathy FSHD 4q35 1   (42, 43, 44, 45)
Factor X deficiency homozygous Factor X  1  (46)
Familial Adenomatous Polyposis APC 1   (47)
Familial hypertrophic cardiomyopathy MYH7 1   (48)
Familial hypophosphatemic rickets (XLH)  PHEX   1 (49)
Fragile X FraX (deletion)   1 (50)
Frontotemporal dementia with parkinsonism-17 MAPT 1   (51)
Hemoglobinopathy beta-globin 1   (52)
Hemophilia A Factor VIII   1 (53, 54, 55)
Hemophilia B  Factor IX   1 (56, 57, 58, 59)








Disease Gene AD  AR  X-L reference
Hutchinson-Gilford progeria LMNA 1   (61)
Hyperparathyroidism–jaw tumour syndrome HRPT2 1   (62)
Hypoparathyroidism sporadic isolated form CASR 1   (63)
Kallmann syndrome  FGFR1 1   (64)
Lesch-Nyhan syndrome HPRT   1 (65)
Li-Fraumeni P53 1   (66)
Lowe syndrome  OCRL1   1 (67)
Marfan FBN1 1   (68)
MODY 5 HNF-1beta 1   (69)
Neurofibromatosis 1 NF1 1   (70)
Ornithine transcarbamylase deficiency OTC   1 (71)
Osteogenesis imperfecta COL1A1/COL1A2 1   (72, 73, 73, 74,  
     75, 76)
Otopalatodigital syndrome (OPD) spectrum  FLNA   1 (77, 78)
Progressive external ophthalmoplegia  ANT1 1   (79)
Progressive external ophthalmoplegia C10Orf2(Twinkle) 1   (80)
Pseudoachondroplasia COMP 1    (81, 82)
Renal coloboma  syndrome PAX2 1    (83, 84, 85)
Resistance to thyroid hormone (RTH) TRbeta 1    (86)
RETT MECP2   1  (87, 88)
Subcortical band heterotopia  DCX   1  (89, 90)
Thanatophoric dysplasia type I (TDI) FGFR3 1    (91)
Tuberous sclerosis complex TSC1/2 1    (92, 93)
X-linked alpha thalassaemia mental retardation 
syndrome ATRX   1  (94)
X-linked form of chronic granulomatous 
disease (CGD) CYBB   1  (95)
X-linked dyskeratosis congenita  DKC1   1  (96)
X-linked mental retardation (XLMR) ARX   1  (97)
X-linked mental retardation with microphthalmia 
and microcephaly PQBP1   1  (98)
X-linked myotubular myopathy  MTMI   1  (99, 100)
X-linked severe combined immunodeficiency IL2RG   1  (101, 102)
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Abstract
We describe a patient with somatic mosaicism of a point mutation in the dystrophin gene causing benign muscular dystrophy with an
unusual asymmetrical distribution of muscle weakness and contractures. To our knowledge this is the first patient with asymmetrical
weakness and contractures in an ambulatory patient with a dystrophinopathy.
q 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Duchenne muscular dystrophy (DMD) is a progressive
muscular dystrophy leading to death in early adulthood. In
the Netherlands the prevalence is about one in 4000 boys
[1]. Signs and symptoms due to symmetrical weakness of
the hip muscles and lower proximal limb muscles occur in
early childhood. Before the age of 13 DMD patients are
wheelchair-bound. They usually die due to cardiac arrest or
respiratory failure [2] although of late a much more
protracted course is observed since artificial ventilation is
increasingly employed. About one third of the patients
presents non-progressive intellectual impairment. The
diagnosis is usually suspected in boys with symmetrical
weakness and the serum creatine kinase (CK) activity of
more than ten times the upper limit of normal. DMD is
caused by mutations in the dystrophin gene on the X
chromosome band p21. Most patients have a deletion of part
of the gene (60%), about 5% have a duplication, the
remaining 35% have a frameshift, a nonsense or a splice site
mutation [3].
Becker muscular dystrophy (BMD) is also caused by
mutations in the dystrophin gene. Usually these mutations
retain the reading frame and generate a shortened and
reduced amount of the protein. Mutations that disrupt the
reading frame cause a premature termination and a loss of
dystrophin and lead to DMD [2]. The phenotype of BMD is
similar to that of DMD but in terms of skeletal muscle and
cardiac involvement, the course is much milder.
One third of the patients have the disease as the result of a
new mutation. Mothers of patients with apparent de novo
mutations, were shown to transmit the mutation a second
time, while these mothers were not carrying the mutation in
lymphocytes. This phenomenon is known as germinal
mosaicism. Empirical data revealed a recurrence risk for
male pregnancies of around 14–20%, associated with
transmission of the X chromosome of their affected son
[4,5]. Somatic mosaicism has been described in a number of
mothers of Duchenne patients and in one Duchenne patient
and possibly in a maternal grandfather, who has three DMD
grandsons from his three daughters [3,4,6–11].
Here we describe a patient with an unusual phenotype
(asymmetrical muscle weakness and contractures) caused
by somatic mosaicism of a point mutation in the dystrophin
gene.
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2. Patient and methods
2.1. Case report
The patient was born after a normal pregnancy, birth
weight was 2700 g. He walked at the age of 18 months. At 6
years of age he was diagnosed with psychomotor retardation
of unknown cause. He attended a school for mildly
intellectually impaired children and he never learned to
read or write. Currently he lives ‘semi independently’ in a
small group with supervision.
At the age of 8 years an abnormal gait was observed.
Gradually, increasing atrophy and weakness of the muscles
of the right leg, scoliosis and contractures became apparent
prompting referral to a neurologist who ascribed these
symptoms to a presumed perinatal trauma despite a normal
electro-encephalogram (EEG) and brain computed tom-
ography (CT).
Neurological examination at the age of 30 showed
atrophy of the muscles of the upper arms, pectoralis
major right more than left and the thighs, right more than
left (Fig. 1). The left calf was hypertrophic (Fig. 2).
There was moderate weakness of the shoulder girdle
muscles and right peroneal muscles and severe weakness
of the upper arm, pelvic girdle, thigh and calf muscles.
Remarkably, Gowers’ phenomenon was negative. He was
not able to walk on tip-toe nor on his right heel.
Contractures at the right shoulder, elbows (left more than
right, Fig. 1) and of the finger flexors were noticed.
Reflexes were negative except the left knee and left
Achilles tendon. A depigmented nevus was present at the
back on the left side of the chest.
Creatine kinase (CK) activity was 3000 IU/l
(normal , 190 IU/l). Electromyography (EMG) showed
myopathic changes. A muscle biopsy taken from the
vastus lateralis muscle of the left leg showed necrotic
fibers, occasional regenerating fibers and a marked
variation in the size of muscle fibers. There were
numerous pycnotic nuclear clumps, and atrophic fibers
showed an increase in non-specific esterase activity.
There was endomysial fibrosis and liposis. The histo-
logical pattern was consistent with muscular dystrophy.
The cardiologist was consulted once the diagnosis was
made. Ultrasound investigation of the heart was normal. The
electrocardiogram (ECG) showed an electric semivertical
Fig. 1. Note the atrophy of the upper arms (left more than right), of the right
leg and of the elbow contractures.
Fig. 2. Note the hypertrophy of the left calf.




heart axis, QRS time of 0.08 s with a high RS ratio right
precordial and in the caudal and lateral leads rather deep
Q’s. This finding is compatible with abnormalities observed
in patients with Becker muscular dystrophy.
Karyotyping showed a normal male pattern, 46, XY.
2.2. DNA analysis
DNA was extracted from the patient’s whole blood,
according to the method of Miller [12]. Multiplex
polymerase chain reaction (PCR) was performed according
to Chamberlain and Beggs [2] and Southern blotting was
after Bakker and den Dunnen [13]. Approximately 200 ng
of the PCR product generating the truncated translation
product was used for sequence analysis. Sequencing was
performed using the Big Dye Terminator Sequencing kit
(Applied Biosystems, Nieuwekerk a/d IJssel, the Nether-
lands) on ABI PRISM 310. Since a PstI restriction site
present in exon 64 is abolished by the mutation, the
percentage of lymphocytes containing the mutation could be
determined by a quantitative PCR analysis for exon 64 on
genomic DNA. After quantitative PCR using a fluorescently
labelled primer, the PCR product was digested with PstI
followed by electrophoresis of the PCR products on an ALF
DNA sequencer analyser (Amersham Pharmacia Biotech).
The relative peak areas were measured.
2.3. PTT assay
RNA was isolated from muscle tissue specimens and
whole blood using RNAzol (Campro Scientific, Veenen-
daal, the Netherlands) according to the manufacturer’s
protocol. Reverse transcriptase-polymerase chain reaction
(RT-PCR) and the protein truncation test (PTT) was
performed as described by Roest [14].
2.4. Immunohistochemistry
Serial unfixed cryostat sections of the muscle specimen
of the patient were studied for dystrophin and spectrin
expression. The following antibodies were used against
dystrophin: NCL-DYS1, NCL-DYS3 (Novocastra Labora-
tories Ltd., Newcastle upon Tyne, UK), Mandys108 [15]
and spectrin (NCL-SPEC1 Novocastra). The immunohisto-
chemical stainings were done as described previously [16].
3. Results
Immunohistochemical analysis of dystrophin revealed a
mosaic pattern of positive and negative staining muscle
fibers using several dystrophin antibodies (Fig. 3). Western
blotting showed a reduced amount of dystrophin (not
shown).
In genomic DNA extracted from lymphocytes no
abnormality was found by multiplex PCR and quantitative
Southern blot analysis. mRNA from the muscle biopsy was
studied using the PTT analysis yielding two bands of one
fragment corresponding to exons 59–68 as can be seen in
Fig. 4, indicating mosaicism. Sequencing of the RT-PCR
product showed a possible point mutation, in exon 64
leading to a premature stopcodon of the dystrophin gene,
although the band was weak. Thereupon genomic DNA was
sequenced and the mutation was confirmed at position
9554C ! T; Q3116X.
The percentage of the mutated allele in DNA from
lymphocytes was calculated to be 75% according to the
method described in Section 2.2 of patient and methods.
DNA analysis in lymphocytes of the patient’s mother did
not show the point mutation.
4. Discussion
The patient reported by us is remarkable because of the
peculiar phenotype and the mosaicism. As stated before,
patients with BMD have progressive symmetrical muscular
weakness and contractures only appear in due course,
namely when patients become wheelchair-bound. Our case
had asymmetric weakness and prominent contractures while
he was still ambulatory. In addition, muscle biopsy showed
a combination of dystrophy and neurogenic changes.
Therefore the differential diagnosis was the following:
facioscapulohumeral dystrophy, spinal muscular atrophy
and dystrophinopathy. DNA analysis for these muscle
disorders did not show any abnormality. However, only
quantitative PCR and Southern blotting of the dystrophin
gene were done, which only reveals large deletions or
duplications. Subsequent immunohistochemical dystrophin
analysis showing a mosaic of dystrophin negative and
positive fibers, led way to the diagnosis.
It is known that the skeletal muscles of DMD patients
may have some dystrophin positive fibers [17]. The most
likely explanation of these so-called revertant fibers, is a
second site in-frame deletion. In our patient the wild type
allele as well as the point mutation were present both in
lymphocytes and in skeletal muscle, indicating that we are
dealing with a true somatic mosaicism.
About one third of DMD and BMD patients are
intellectually impaired, as is our patient. The cause of the
impairment is not known. A correlation was found with the
loss of Dp140 regulatory sequences. Dp140 is a dystrophin
isoform with predominant expression during foetal brain
development. The promoter and first exon lie in the intron
between exon 44 and 45 [18]. In our patient the mutation is
located in exon 64. The point mutation in his dystrophin
gene causes premature translation termination leading to
absence of dystrophin in the affected cells, which is typical
for DMD. The most likely explanation of the mental
impairment in our patient is that the proportion of brain cells
with the mutation is rather high. Family history and physical





examination did not point to another cause for the
intellectual impairment.
Somatic mosaicism has been previously described in six
carriers [3,4,6–9] and in two male patients with a
dystrophinopathy [10,11].
Lebo et al. [10] described a grandfather with an elevated
CK, striking muscle weakness and atrophy in the right arm
and shoulder in the C5–6 innervated myotomes. Each of his
three daughters had a son with DMD. Molecular analysis
showed the three grandsons had inherited the grand paternal
X chromosome. Certainly the grandfather must have had
germinal mosaicism, a somatic mosaicism is possible
because of his clinical picture. Unfortunately, this could
not be confirmed at the molecular-genetic level since the
family was further uncooperative. Saito et al. [9] reported on
a classical DMD patient who had a deletion of exon 1–7 in
the lymphocytes. His mother and the patients’ sister did not
carry the deletion. Post mortem DNA investigation showed
the presence of the deletion in ectodermal and endodermal
tissues. In some mesodermal tissues (temporalis, sterno-
cleidomastoid, diaphragm muscles and the kidney) the
deletion was absent at the DNA level whereas in other
mesodermal tissues the deletion was present, indicating a
somatic mosaicism. Dystrophin expression in muscles
showed no dystrophin in some muscles, in a few muscles
a mosaic pattern was found and in the diaphragm dystrophin
was detected in every fiber. They suggested that the deletion
might have occurred early during embryogenesis because
all cells of the ectoderm and the endoderm carried the
deletion while in the mesoderm a somatic mosaicism was
found.
Our patient illustrates a somatic mosaicism of a point
mutation in the dystrophin gene which made the phenotype
of the dystrophinopathy (with a disruption of the reading
frame), milder. The spectrum of dystrophinopathies can yet
be extended to asymmetrical weakness and early
contractures.
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Duchenne muscular dystrophy (DMD) is the most common inherited
neuromuscular disease. After identification of the mutation in the index
patient, family members can be reliably investigated. Carriers should be
informed about their risk of having offspring with the disease and about
their own risk for cardiomyopathy for which regular cardiac surveillance is
recommended. In a small country like the Netherlands with well-organized
genetic services, one would expect that most DMD families are adequately
informed about the above mentioned risks for carriers. We have
investigated whether women at risk had been tested at a molecular level.
In the national Duchenne/Becker database 311 DMD and 99 Becker
muscular dystrophy (BMD) patients had been registered up to 1 July 2009.
These patients were asked to give information about the number of sisters
and maternal aunts of the DMD/BMD patient and anything that was
known about their genetic status and that of the mother. This information
was compared with the information known at the genetic laboratory.
Thirty-five of 104 adult sisters/maternal aunts of DMD patients with a
50% risk of being a carrier and 45 of 148 adult women with a 4.3% risk
because of germ line mosaicism for DMD had not been tested by DNA
analysis. Our study indicates that about one third of the potential carriers
have not been tested. Given the possible far-reaching clinical
consequences of being a carrier, further studies are needed to investigate
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Duchenne muscular dystrophy (DMD) is a pro-
gressive neuromuscular disease. Most patients
become wheelchair bound before the age of 12,
and their mean age of survival is 26 (1). DMD
has an incidence of roughly 1 in 3500 (28.5 per
100,000) live male births (2). DMD is the most
common X-linked recessive muscle disease and is
caused by a mutation in the dystrophin-encoding
DMD gene on the X chromosome which results
in the absence of dystrophin in the muscles of the
patient. Becker muscular dystrophy (BMD) is a
less common and a milder form of dystrophinopa-
thy. Dystrophin in the BMD muscle is present but
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In two-thirds of the patients DMD is inherited
from the mother, implying that the sisters of
the patient have a 50% risk of being a carrier.
In one third of the patients the mutation has
arisen de novo (3). However, in the latter cases the
mutation may be present in the mother as a germ
line mosaicism, in which case the sisters have an
estimated 4.3% risk of being a carrier (4).
Because DMD is a devastating disease for which
there is no curative therapy so far, much emphasis
has been put on prevention. For known DMD
families, offering genetic counseling to women at
risk is the first step toward prevention. The women
are informed about their risk of being a carrier,
the available test, the recurrence risks and their
reproductive options.
Another aspect relevant to female carriers is
their own health. It is estimated that about 10%
of female carriers develop dilated cardiomyopa-
thy (5). A recent study in the United States has
shown that only 62.9% of the carriers are aware
of their risk for cardiomyopathy (6).
At a consensus conference held in 2002, it was
agreed that female carriers should be advised to
start cardiologic examination at diagnosis or at the
age of 16 with follow-up examinations at least
every 5 years (7).
In the Netherlands most, and from 1997 onwards
all, DMD DNA diagnostics is carried out in the
genetic laboratory in Leiden. For most of the
children with DMD, a molecular test is performed
according to the best practice guidelines (8), and
genetic counseling is offered to family members.
The Netherlands is a small country with 17 million
inhabitants and clinical genetic departments in
each of the eight university hospitals. Each DMD
family can have counseling within a distance of
<100 km from their home. During our work as
clinical geneticists (A. H-E, M. H. B) and clinical
molecular geneticists (E. B, H. B. G), we have
come across several DMD families in which
women appear to be unaware of their risk of
being a carrier. These families prompted us to
carry out this study (see examples of families
under the Results section). To the best of our
knowledge no studies have been performed on
the results of cascade screening (9) in DMD and
BMD. A study on childless young women at
risk for DMD in Brazil who received genetic
counseling showed that the magnitude of the
genetic risk did not influence the request for DNA
testing (10).
In this study we have investigated whether all
women at risk for carrying the familial mutation
in the DMD gene have been tested at a molecular
level.
Materials and methods
All patients/families that had been registered up
to 1 July 2009, in the Duchenne/Becker database
in the Netherlands (www.lumc.nl/duchenne), were
asked to fill in a questionnaire about the phenotype
of the patient as well as about the family
history as a part of the registration procedure.
The registration started during the spring of
2008.
Registrees were requested to list the number
of brothers, sisters, maternal uncles and mater-
nal aunts of the Duchenne/Becker patient. They
were asked whether each of the male mem-
bers was healthy or affected with DMD/BMD.
They were also asked whether the mother of the
DMD/BMD patients and the other female mem-
bers had undergone carrier testing and if so, were
they carriers.
The information from the questionnaires was
compared to the information known at the genetic
laboratory in Leiden. If two or more individuals
from the same family were registered in the
database, they were included as one family. The
reasons for not including some of the families are
given in Table 1.
In the investigated families where the mother
was a carrier we checked whether the maternal
grandmother, the sisters and the maternal aunts
of the DMD/BMD patient had been tested at a
molecular level at the genetic laboratory.
Subsequently we calculated the number of
women who had a 50% risk of being a carrier.
A woman was defined as having a 50% risk if
she had not been DNA tested, was not an obligate
carrier, had a brother with DMD/BMD and her
mother was a proven carrier. We also calculated
the number of women at a 4.3% risk because of
Table 1. Reasons for excluding 89 of 311 DMD and 36 of 99
BMD families from the study
DMD BMD
Family abroad 6 0
No sample at the Leiden laba 27 10
No information on the
questionnaireb
21 2
Unidentified mutation 18 9




DMD, Duchenne muscular dystrophy; BMD, Becker muscular
dystrophy.
aNo blood sample received by the laboratory in Leiden for a
molecular test. Not known whether the families had been tested
elsewhere.
bInformation on the phenotype of the patient given but the
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germ line mosaicism in the de novo families (4).
Germ line mosaicism is defined as the presence of
two or more genetically distinct cell lines confined
to the precursor (germ line) cells of the egg or the
sperm. In this study, a woman who has a brother
with DMD/BMD was considered to have a germ
line risk even if her mother did not have a muta-
tion in her lymphocytes because of the possibility
of a germ line mosaicism in the mother. Maternal
aunts of a DMD/BMD patient were considered to
have a germ line risk if the mother of the patient
carried the mutation in her lymphocytes and the
carrier status of the grandmother was not known.
In BMD families, the maternal grandfather was not
affected with BMD.
We counted the number of mothers and grand-
mothers tested for carrier status in families who
were sent in before (old family) and after 1 Jan-
uary 1997 (recent family) to see if there was a
possible difference in the number of women tested
in the two periods.
We chose this date as it was exactly in the mid-
dle of the period between 1984, when DNA diag-
nostics of the DMD gene was started in Leiden,
and 2009, the year in which most of this study was
carried out.
The women at risk were divided into two
groups: younger than and older than 16 years
because cardiologic examination is recommended
for carrier women from this age onwards (7). If the
date of birth of a woman was not known, an esti-
mate was made by considering her position in the
pedigree where the ages of other family members
were known.
If, in the families that were included in the
study, the information on the questionnaire about
one or more family members did not match the
information present in the laboratory (Table 2), the
information from the laboratory was used.
Results
On 1 July 2009, 311 Duchenne and 99 Becker
patients had been registered at the national
database. Among these, 89 DMD and 36 BMD
patients were excluded from the study (Table 1),
leaving 222 DMD and 63 BMD patients. The
information in the questionnaire and the labora-
tory was concordant in 186 of 222 (84%, 95%
confidence interval: 79–89%) DMD and in 43
of 63 (68%, 95% confidence interval: 57–80%)
BMD cases. Table 2 shows the reasons for dis-
cordance in 36 of 222 DMD and 20 of 63 BMD
families. Table 3 shows the number of women at
risk in DMD families that had not had a DNA
test. Eighty-six of 155 women with an a pri-
ori 50% risk of being a carrier had not been
tested. This includes 35 of 104 (34%) women older
than 16.
Seventy-seven of 180 women with a germ line
risk had not been tested, including 45 of 148
(30%) women older than 16. It is noteworthy that
we found germ line mosaicism in five de novo
Table 3. Number of women in DMD and BMD families with an
a priori 50% risk of being a carrier and with a 4.3% risk because
of a germ line mosaicism tested or not tested in the laboratory
Women with a 50%
risk







DMD ≥16 year 35 69 104 45 103 148
DMD <16 year 51 51 32 32
Total DMD 86 69 155 77 103 180
BMD ≥16year 3 25 28 9 32 41
BMD <16 year 7 7 1 1
Total BMD 10 25 35 10 32 42
DMD, Duchenne muscular dystrophy; BMD, Becker muscular
dystrophy.
Table 2. Families included in the study where the information about family members on the questionnaire did not match that present
in the laboratory
DMD BMD
Conflicting data on results obtained from DNA test between laboratory and the forma 5/36 (14%) 3/20 (15%)
Family member ‘known’ on the form but unknown in the laboratoryb 8/36 (22%) 2/20 (10%)
Family members not on the form but known in the laboratoryc 8/36 (22%) 7/20 (35%)
No information on female members on the formd 8/36 (22%) 1/20 (5%)
Form confused, no conclusions could be drawn 7/36 (19%) 7/20 (35%)
DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy.
aFemale family member listed as a carrier on the questionnaire but not a carrier according to the DNA test or vice versa.
bFemale family member of an index patient in whom a mutation had been detected in Leiden, listed as a carrier or a non-carrier but
never tested in Leiden.
cNo mention of female family members on the questionnaire but female relatives tested in Leiden or had come to light via testing of
other relatives.
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DMD families. The mutation was identified in
other members of the family who had had a DNA
test.
Table 3 also shows the number of women in
BMD families who had not had a DNA test. Ten
of 35 women in the 50% risk group had not been
tested, including 3 of 28 women (11%) older than
16. Ten of 42 women with germ line risk had not
been tested, including 9 of 41 women (22%) older
than 16.
It is again worth noting that one de novo
BMD family was found to have germ line
mosaicism.
Table 4 shows the results of the DNA test of the
mothers and maternal grandmothers at risk in the
DMD families. In all, 4% of the mothers and 42%
of the grandmothers had not been tested. There
was one notable difference between old and recent
families. Although 33% (95% confidence interval:
18–48) of grandmothers in the old families had not
been tested, this figure was 47% (95% confidence
interval: 35–59) for recent families.
Table 4 also shows the results of the DNA test
of the mothers and maternal grandmothers at risk
in the BMD families. In all, 22% of mothers and
57% of grandmothers had not been tested.
Examples of families
Family A illustrates the use of unreliable tests
for carrier detection and failure to test
the maternal grandmother
The index (IV:4), born in 1975, was diagnosed
with DMD at the age of 3 (Fig. 1 pedigree A).
His older brother (IV:3) who had died at the
age of 4 during a light narcosis had apparently
had the same pattern of walking. Around 1980
the blood (probably creatine kinase (CK)) and
muscle biopsies of the maternal grandmother and
a maternal aunt were tested. They were not found
to be carriers. A mutation was identified in the
index (IV:4) at the age of 13. At the time, only
a pediatrician was consulted. The sister of the
index was tested and was found not to be a
carrier. However, the mother and the maternal
grandmother were not tested. In 1993 DMD
was diagnosed in another 4-year-old child (IV:6)
who carried the familial mutation. Subsequently,
information from the carrier mothers led to the
confirmation of DMD in yet another child (IV:10).
When we contacted the family in 2009 for
permission to publish their pedigree, we learnt that
a son of a sister of the maternal grandmother (III:1)
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DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy.
a‘Old’ family: blood received before 1 January 1997; ‘recent’ family: blood received after 1 January 1997.
bThree DMD mothers had two and one had three children with a mutation.
cSeven maternal DMD grandmothers had an affected sib and one had three children with a mutation.
dOf the 24 carrier BMD mothers, three had inherited the disease from their father leaving 21 grandmothers who were at risk.
eFive BMD mothers had two children and two had three children with a mutation.
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Fig. 1. Pedigrees of remarkable families.
of the index patient had probably also had DMD.
He was ambulatory when he was young but later
became wheelchair bound and developed scoliosis.
Old photographs showed enlarged calves. He died
in 1966 at the age of 16 and was thought to have
been affected with poliomyelitis. We also informed
the mother of the index patient that her sister (III:4)
had a risk of being a carrier. This was particularly
important because her daughter (IV:2) was in her
20s and did not have a family yet.
Family B, an example of germ line mosaicism
Duchenne muscular dystrophy (DMD) was diag-
nosed and confirmed at the molecular level in the
index at the age of 7 (Fig. 1, pedigree B). The fam-
ily history was negative for DMD. A DNA test on
lymphocytes showed that the mother was not a
somatic carrier. However, the sister was found to
be a carrier of the same mutation as her brother,
proving germ line mosaicism in the mother.
Family C illustrates communication problems
within a family
A pregnant woman was referred for genetic coun-
seling because she knew that her mother had had
three brothers who died at a young age and were
possibly affected with DMD. The mother of the
pregnant woman did not cooperate, so a prenatal
test could not be performed. A boy was born. At
the age of 2, he was referred for molecular test-
ing because of suspicion of DMD and a mutation
was detected. Subsequent testing of the mother of
the DMD patient revealed that she was the car-
rier.
Discussion
In 1999, Hoogerwaard et al. (5) reported the
results of a study performed on 129 Dutch carriers
of DMD and BMD. They showed that for these
women, being a carrier not only had consequences
for their offspring but also for their own health,
namely an increased risk for cardiomyopathy.
One would expect that in the last 10 years this
knowledge would have influenced the uptake of
molecular testing of potential carriers. However,
our study shows that even in the Netherlands, with
its well-organized genetic counseling services,
there is still a large number of women in
DMD/BMD families who have not been tested at
the DNA level.
In the 222 of 311 registered DMD families that
could be analyzed, 86 women with a 50% risk
of being a carrier and 77 women with 4.3% risk
because of germ line mosaicism had not been
tested. In general, it is agreed that carrier testing in
minors should be deferred until the child can give
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only women older than 16 it emerges that 34% of
women with a 50% risk and 30% of the women
with a germ line risk had not been tested.
In the 63 of the 99 registered BMD families
that could be analyzed, 10 women with a 50%
risk of being a carrier and 10 women with a germ
line risk had not been tested. The percentages of
women older than 16 who have not been tested in
the BMD families are 11% for women at a 50%
risk and 22% for the women with a germ line risk.
The above percentages of the women at risk are
probably underestimates because we were able to
look at only the first- and second-degree relatives
of DMD/BMD patients.
There could be a variety of reasons why a
woman has not been tested: she does not wish
to have (more) children, she relies on the result
of an earlier (unreliable) test by serum creatine
kinase measurements or muscle biopsy (family
A), has moral or religious objections to testing,
she is unaware of her risks because of lack of
communication within the family or she is not
able to undergo reliable testing because her family
does not cooperate (family C). Molecular testing
of the maternal grandmother in DMD families,
where the mother is a carrier, is important for
genetic counseling. Two-thirds of these maternal
grandmothers are expected to be carriers (3). In
our study, the genetic status of 48 maternal
grandmothers was unknown in the 114 DMD
families where the mother was a carrier. More
grandmothers were not tested in recent families
(47%) than in old ones (33%). Besides the reasons
given above for sisters and maternal aunts, there
may be additional reasons why grandmothers had
not been tested. These include death, anticipated
guilt feelings should a mutation be detected or
lack of understanding of the inheritance pattern
especially if her healthy sibs have healthy sons.
Our observations illustrate the importance of
drawing attention to the germ line risk of which
many doctors and patients are not aware. In fact
the germ line risk is 4.3% (4) and as mentioned
earlier, we found proven germ line mosaicism in
five DMD families and in one BMD family. In
family B the healthy sister who asked for genetic
counseling prior to starting a family turned out to
be a carrier of the mutation, which was present
in the germ line cells of the mother. With this
knowledge, she and her partner can make informed
choices in planning their family. Furthermore, she
could be referred for periodic examination for
cardiomyopathy.
Agreement between information in the question-
naire and that present in the laboratory was high for
both DMD (84%) and BMD (68%) families, but
more women from the DMD families were aware
of their risks. This may be because some BMD
patients with a very mild phenotype may not see
the importance of informing their relatives.
In 16% of the DMD and 32% of the BMD
families, there was a discrepancy between the
information obtained via the questionnaire and
that known in the laboratory. Among the reasons
given for the discrepancy in Table 2, the first
two are particularly worrisome. The first reason,
conflicting data on results DNA test between
laboratory and the form, demonstrates that in five
DMD and three BMD families women think they
are carrier/non-carrier whereas the result of the
DNA test showed the opposite. The second reason,
family member known on the form but unknown in
the laboratory, shows that in eight DMD and two
BMD families women think that they have been
tested whereas they have not been tested. Possible
explanations could be that either the respondent
was not well informed or that the women had been
tested elsewhere (DMD diagnosis was offered in
Groningen before 1997), even though the mutation
in the index patient had been detected in Leiden.
The information on the questionnaire will also
have been influenced by the memory and family
ties of the respondents.
Our results show that even in the Netherlands
genetic counseling and follow-up of families of
Duchenne and Becker patients are incomplete.
As a consequence, female family members are
not informed of their risk of being a carrier. In
some cases, this may have led to the birth of an
affected boy. Adequate cascade carrier screening
would have been helpful in these cases. The
results indicate that our standards of care need to
be substantially improved to enable us to offer
a possibility of prevention to all at-risk family
members.
The General Medical Council in the United
Kingdom issued a guidance named ‘Confidential-
ity’ in October 2009 (12). For the first time, giving
genetic information to protect the family has taken
precedence over protection of the privacy of an
individual (13).
According to the new advice, doctors should be
told explicitly that it may be justified to reveal
information in the interest of relatives even if
the patient objects. Such information could, for
example, alert family members with a genetic pre-
disposition to cancer to the need for surveillance or
treatment, or influence decisions on reproduction.
Both these aspects are valid also for DMD/BMD
families: carrier women need to undergo regular
cardiac surveillance and can use the information to
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In a recent review on diagnosis and management
of DMD (14, 15), genetic counseling is indicated
as a part of the diagnostic process. However, so far
the question of how the family should be informed
has not been addressed. The question why so
many women at risk have not been tested at
a molecular level will be the subject of further
research. For women relying on the result of an
earlier unreliable test, for example serum creatine
kinase measurements, it is clear that now there
is a more reliable molecular test available. An
ethical dilemma arises in approaching a woman
who has not been tested because she was not
informed about the risk of being a carrier, as a
result of either lack of communication or lack of
cooperation within the family. In the UK guidance
of the General Medical Council, it is suggested that
the patient’s identity should not be disclosed in
contacting and advising the family members about
their risks, if practicable. These last two words
are crucial for it is often impossible not to disclose
the patient’s identity. It is also not always possible
to contact family members without the help of
the patient. One form of lack of cooperation by
the family members can be their refusal to provide
a blood sample for identifying the mutation. This
problem will be solved in the future with the
availability of newer molecular techniques.
At present, in the genetic counseling practice
in the Netherlands, the index case is handed a
letter with which he or she can inform the family
members. In this way the privacy of the index
is protected because he or she can choose not
to distribute the family letter. In a recent study
by Van der Roest et al. (16), 88% of the family
letters were distributed in the family and as a
result 57% of the family members of patients
with a high-risk genetic cardiac disease underwent
screening. For diseases such as hereditary cancer
with preventive options, on average 50% of family
members undergo genetic testing (17, 18).
There is an ongoing debate on whether a more
active approach of family members is justified,
considering the fact that such a high percentage of
family members does not undergo genetic testing.
This study should help in bringing this problem
under the attention of the doctors and those who
care for DMD/BMD families. Thus, more women
can be made aware of the implications of being a
carrier, both for their offspring and for themselves,
and can be offered molecular testing.
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An urgent need for a change in policy revealed
by a study on prenatal testing for Duchenne
muscular dystrophy
Apollonia TJM Helderman-van den Enden*,1,4, Kamlesh Madan1, Martijn H Breuning1,
Annemieke H van der Hout2, Egbert Bakker1, Christine EM de Die-Smulders3 and Hendrika B Ginjaar1
Prenatal diagnosis for Duchenne muscular dystrophy (DMD) was introduced in the Netherlands in 1984. We have investigated
the impact of 26 years (1984–2009) of prenatal testing. Of the 635 prenatal diagnoses, 51% were males; nearly half (46%)
of these were affected or had an increased risk of DMD. As a result 145 male fetuses were aborted and 174 unaffected boys
were born. The vast majority (78%) of females, now 16 years or older, who were identified prenatally have not been tested for
carrier status. Their average risk of being a carrier is 28%. We compared the incidences of DMD in the periods 1961–1974
and 1993–2002. The incidence of DMD did not decline but the percentage of first affected boys increased from 62 to 88%.
We conclude that a high proportion of families with de novo mutations in the DMD gene cannot make use of prenatal diagnosis,
partly because the older affected boys are not diagnosed before the age of five. Current policy, widely accepted in the genetic
community, dictates that female fetuses are not tested for carrier status. These females remain untested as adults and risk
having affected offspring as well as progressive cardiac disease. We see an urgent need for a change in policy to improve the
chances of prevention of DMD. The first step would be to introduce neonatal screening of males. The next is to test females
for carrier status if requested, prenatally if fetal DNA is available or postnatally even before adulthood.
European Journal of Human Genetics advance online publication, 6 June 2012; doi:10.1038/ejhg.2012.101
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INTRODUCTION
Duchenne muscular dystrophy (DMD), an X-linked recessive disease
leading to relentless loss of muscle tissue, is clinically diagnosed
around the age of five.1 The mean age of survival is 25 years. The
incidence of DMD is roughly 1 in 3500 live male births.2 Becker
muscular dystrophy (BMD), a milder variant of DMD, has an
incidence of 1 in 18 450 males. De novo mutations account for one-
third of the DMD patients.3 The importance of prevention has been
much emphasized as no curative therapy is available. Women at risk
can be offered genetic counseling and carrier testing. Options for
carrier women include prenatal diagnosis, preimplantation genetic
diagnosis (PGD) or the use of donor eggs. With prenatal diagnosis,
no further testing to determine the carrier status is done if the fetus is
female. A male fetus is tested by direct analysis for a known familial
mutation to determine if he is affected. If a familial mutation is not
known, haplotyping is used to determine whether the fetus has a high
risk of being affected with DMD or BMD. The birth of these boys can
be prevented by terminating the pregnancy. With PGD, either female
or unaffected male embryos can be selected and transferred to the
uterus. First trimester prenatal diagnosis for dystrophinopathy has
been available in the Netherlands since 19844 and PGD since 1995.5
However, these strategies do not prevent the birth of boys with a
de novomutation. The aim of this study was to determine the effect of
genetic counseling and the use of prenatal testing and PGD on the
occurrence of DMD and BMD in the Netherlands.
MATERIALS AND METHODS
Patients
We have used two sets of data, a postnatal cohort 1993–2002 to determine the
incidence of DMD and a prenatal cohort 1984–2009 to examine the results of
prenatal diagnosis. We have also included the result of PGD in the period
1995–2009.
Incidence
Most, and from 1997 onwards all, DNA diagnostics for DMD/BMD in the
Netherlands has been done in the Laboratory for Diagnostic Genome Analysis
at the Leiden University Medical Center. A mutation in the DMD gene has
been identified in more than 1000 patients in our laboratory since the start of
the service in 1984. The incidence of DMD was determined from the number
of DMD males born in the period 1993–2002 from our database in Leiden and
from the total number of live male births obtained from Statistics Netherlands
(www.cbs.nl). We chose this 10-year period, because before 1993 not all DMD
patients were referred to our laboratory for DNA analysis and not all patients
born after 2002 had been clinically diagnosed yet. The diagnosis of dystrophino-
pathy was considered certain only when a mutation that confirmed the clinical
diagnosis had been identified. This was done with MLPA and if no deletion or
duplication was found, high resolution melting curve analysis6 was used.
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The incidence of DMD in the birth cohort 1993–2002 was compared with
the incidence of DMD patients born in the period 1961–1974 in the
Netherlands.7 We further split the data on incidences from the 10-year
period into two 5-year periods: 1993–1997 and 1998–2002 to see if there
was a decline in the incidence in the second period with respect to the first.
Finally, we examined the family trees for the birth cohort 1993–2002 to
determine: (1) the carrier status of the mother, (2) whether the affected boy
was the first affected patient in the family and (3) if the boy was not the first
affected, whether the oldest affected boy was older than five at the time of the
birth of the younger one. We then compared the proportion of first affected
patients in this period to the proportion in 1961–1974 to determine if prenatal
testing had been used by DMD families to prevent the birth of subsequent
affected boys.
Pearson’s w2-test was used to calculate the significance of difference between
the incidences.
Prenatal tests and PGD
Every woman in the Netherlands with an increased risk of having a son with
DMD/BMD is offered prenatal testing. PGD is done only upon request. We
examined the results of all the prenatal tests done in 26 years (1984–2009) and
PGD in 15 years of (1995–2009). The prenatal data are from the laboratories in
Leiden and the University Medical Center Groningen. Prenatal diagnosis was
done in Groningen also after 1997 in women from families wherein the
mutation had been identified there earlier. We recorded the date, the type and
the outcome of the test and the place of residence of the pregnant woman.
Tests performed on samples from outside the Netherlands were excluded from
the analysis. The PGD data on DMD/BMD cases was obtained from




In the 10-year period (1993–2002) 216 boys with DMD were born.
With the exception of one boy born in 1994, none of them had been
tested prenatally. The clinical diagnosis in all the 216 boys was
confirmed by postnatal DNA analysis. The incidence of DMD was
about 1 in 4700 male live births (for the exact figures and confidence
intervals see Table 1). The incidence reported for the period
1961–1974 is about 1 in 4200 male live births7 (see Table 1). There
was no significant difference between the incidences in these two
periods (P¼ 0.227). There was also no significant difference
(P¼ 0.114) between the incidences in the two 5-year periods,
1993–1997 (1:4200) and 1998–2002 (1:5200).
Percentage of first affected patients in the DMD families
Of the 216 boys born with DMD in the period 1993–2002, 189 (88%)
were the first affected patient in the family (95% CI: 83–92%).
Analysis of maternal lymphocytes showed that 98/189 had a carrier
mother and in 91/189 the mutation had arisen de novo, but
mosaicism was not excluded in the latter group. In 27/216 (12%)
families there was an older affected family member. One of the 27 was
tested prenatally, the parents accepted the 33% risk indicated by
haplotyping and an affected boy was born in 1994. The remaining
26/27 families were not known to us before the birth of the second
boy; in 12 of these, the older affected boy was younger than 5 years.
In the cohort of 1961–1974, 62% (95% CI: 57–66%) of the boys
with DMD did not have an affected DMD relative.7 This implies that
62% were the first affected in the family, in contrast to the above
mentioned 88% in the period 1993–2002.
Prenatal diagnosis
Figure 1 shows the results of 635 prenatal samples, including 28 from
Groningen, referred for DMD/BMD between 1 January 1984 and 31
December 2009. There were 322 (51%) male fetuses, 290 (46%)
female and in 23 (about 4%) testing was not completed. For details
see Figure 1. Figure 2 shows the number of female and male fetuses
identified per year. The decreasing number of females in recent years
can be attributed to the increasing use of maternal blood for fetal sex
determination.
Male fetuses. Figure 1 shows that 147 of the 322 male fetuses (46%)
were affected or had an increased risk of having DMD/BMD. The
number of these males found per year is shown in Figure 3. Figure 4
shows that the number of tests based on haplotyping has gradually
reduced over the years as the number of cases identified by direct
mutation analysis has increased. However, haplotyping is still used
if no DNA is available, because the index patient is deceased or
if prenatal testing is done in cases without a familial mutation. The
pregnancy was terminated in 145 of the 147 cases of affected or at risk
fetuses and two affected boys were born. The first is the above
mentioned boy born in 1994. The second, born in 1995, had BMD
and the pregnancy was continued on grounds that all
three affected family members were wheelchair bound only after the
age of 50.
There were 175 male fetuses with no increased risk (Figure 1) and 174
unaffected boys were born. There was one false-negative result where a
deletion was missed in 1989 by Southern blotting and multiplex PCR
and an affected boy, born in 1990, was diagnosed in 1993. Further
investigation revealed that the fetal DNA had been contaminated with
5–10% DNA from another person but we were unable to trace where or
when the contamination had taken place. This was before contamination
tests were implemented in our routine diagnostic laboratory in 1993.
Female fetuses. The carrier status of a female is usually determined
postnatally at the age of 16 or later. In general, therefore, no molecular
testing is done if a fetus is found to be a female. We divided the
290 females into two groups: those that were diagnosed before and
after 1 January 1993. The 111 girls that were diagnosed before 1993
are now between 16 and 26 years old (see Figure 1). Only 24 of
the 111 have been tested for the familial mutation, at an average
age of 17.5 years (Figure 1). This means that 87/111 (78%) have not
yet been tested. The average risk of being a carrier for these girls is
28% (Figure 1). Their mothers are either proven carriers, have an
increased risk determined by haplotyping or are potential germ-line
mosaics.8
As an exception to the rule, 6 of the 179 females diagnosed after
1993 were tested before adulthood, 3 prenatally and 3 postnatally.
Two fetuses were tested because they were at a risk of being affected as
they were 45,X/46,XX mosaics. The mother in the third case was
afraid that she might be a germ-line mosaic and did not want a
carrier daughter. One girl was tested at 2 because of delay in motor
development. Two girls were tested at the request of the girls and their
parents, one at the age of 11 and the other at 16.








1993–1997 493769 117 1:4220 (3573–5154)
1998–2002 518210 99 1:5234 (4373–6518)
1993–2002 1011979 216 1:4685 (4134–5406)
1961–1974 (van Essen et al7) 1673791 397 1:4215 (3738–4831)
Abbreviations: CI, confidence interval; DMD, Duchenne muscular dystrophy.
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Preimplantation genetic diagnosis for dystrophinopathies
Sixty-six couples were referred for PGD for a dystrophinopathy in the
period 1995–2009. Most withdrew following extensive genetic coun-
seling; only 14 couples received the treatment with a total of 31 IVF/
PGD treatment cycles. The gender was determined using fluorescence
in-situ hybridization in all cycles and one or two female embryos were
transferred to the uterus. These treatments resulted in the birth of
seven healthy girls, three singletons and two sets of twins.
DISCUSSION
Effect of prenatal testing on the incidence of DMD
Our study has shown no significant difference in the incidence of
DMD between the birth cohorts 1961–1974 (1:4200)7 and 1993–2002
(1:4700), or between the two 5-year periods 1993–1997 (1:4200) and
1998–2002 (1:5200). Similar studies in Denmark and Canada have
also shown no decrease in the incidence in the last three decades,9,10
but the incidence in Australia has declined.11
It should be noted that the methods by which the data were
obtained in the two periods were different. DMD patients in the birth
cohort 1961–1974 were diagnosed at a time when molecular testing
and immunohistochemical analysis of dystrophin in muscle tissue
were not yet possible.7
Effect of prenatal testing on known families
Prenatal testing has provided women in DMD families the possibility
of preventing the birth of an affected child. In the period of 26 years,
145 male fetuses that were affected or had a high risk of dystrophino-
pathy were aborted.
The most significant positive effect of prenatal testing in this
period was the birth of 174 unaffected boys in DMD/BMD families.
The parents in these cases have been spared the emotional burden of
322 (50,7%) males
147 (46%)
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not to be a carrier
4 reason not
traceable
* 174 unaffected boys born and one case of false-negative result (see text). 
** Three cases tested prenatally and three postnatally for carrier status (see text). 
*** Includes ten cases with a 4.3% risk due to germ-line mutation.  
****  Termination of pregnancy after gender determination or karyotyping. 
Figure 1 Results of 635 prenatal diagnoses in the period 1984–2009.
Need for a change in policy for DMD
ATJM Helderman-van den Enden et al
3
European Journal of Human Genetics
73
A




having to abort a possibly healthy boy, which was always the major
drawback of prenatal diagnosis of X-linked disorders by sex determi-
nation only. PGD can offer some families the possibility of having
children without the burden of any abortion at all.
Prenatal testing: no option for parents of most DMD boys
Prenatal diagnosis is offered only to women who have a known
increased risk. A large proportion of women, 189/216 (88%) who
gave birth to a boy in the period 1993–2002 could not make use of
this preventive measure, because the affected patient was the first in
the family. This high percentage can be explained as follows. One in
three DMD patients is thought to have a de novo mutation but
empirical data show the number of de novo deletions, the most
common type of mutation in the DMD gene, to be as high as 57%.11
Our own study indicates that a new mutation arose in 48%. However,
even if we consider the theoretical figure of one in three, one must
remember that the mutation is de novo not only in one-third of the
patients but also in one-third of the other two-thirds of the mothers
who are carriers. In theory, therefore, the total number of DMD
patients who are the first affected in the family is at least 56%
(1/3 de novo in the patient plus 1/3� 2/3 de novo in the carrier
mother). This figure is remarkably close to the empirical data from
the sixties where the percentage of sporadic DMD patients was 62%.7
Thus, the high number of sporadic DMD patients appears to be
caused by the result of a relatively high rate of spontaneous mutations
that have arisen in the mother, in the grandparents or in even earlier
generations but which have not yet manifested in the birth of an
affected offspring.
Prenatal diagnosis was also not an option for most of the
remaining 12% (27/216) of the families with an older affected
relative. Information about DMD in the older boy was not available
at the time of birth in 26/27, in nearly half of them (12) the older
boy was younger than 5 years, the age at which DMD is generally
diagnosed. The parents could have opted for prenatal diagnosis had
they known about the older boy. To our knowledge, three studies
have addressed the question of whether neonatal screening leads to




































Figure 2 The number of female/male fetuses per year.




































Figure 3 The number of male fetuses with or at an increased risk of having DMD/BMD per year in the period 1984–2009.
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prenatal testing in subsequent pregnancies. A pilot study in 1993
showed that only 2/7 pregnancies of a second child were monitored by
prenatal diagnosis. The authors emphasize the influence of religion
and/or extremely poor social conditions in the other five families.12
Two studies from 1998 have shown that families do assess their
reproductive choices as a result of earlier diagnosis; 2/2 and 10/12
subsequent pregnancies were monitored.13,14 Data from our prenatal
cohort 1984–2009 (Figure 3) show that known DMD families do use
prenatal diagnosis to prevent the birth of affected boys. A questionnaire
held among DMD families in the Netherlands indicates that parents are
in favor of early detection.15 Introduction of neonatal CK screening of
males would improve the chances of prevention of DMD in the future.
Increase in the percentage of first affected patients
The proportion of first affected boys in the family has increased
significantly from 62% in the birth cohort 1961–19747 to 88% in the
cohort 1993–2002. This indicates that the DMD families are more
aware of their increased risk and have made use of prenatal tests to
prevent the birth of a second affected boy as is shown in Figure 3. It is
also possible that some families with one affected child may have
decided not to have any more children.
Female fetuses and carrier testing
All professional recommendations agree that carrier testing of minors
for X-linked recessive disease should ideally be deferred.16 The
guidelines emphasize that the decision to test should be made by
the child when it reaches the age of maturity because in general
carrier testing has implications for the future reproductive prospects
of that child only and not of her parents. This view is based on the
basic ethical principle of informed consent, by which an individual
can freely give, without external pressure, her/his consent to be tested
after being informed of the benefits, risks, procedures and other
pertinent information relating to the carrier test. It is not possible to
predict whether or not a female heterozygous for a mutation in the
DMD gene will manifest any signs of the disorder. Also, being a
carrier of DMD is not lethal, as it is for boys who are affected.
The current policy for DMD, therefore, is that female fetuses are not
tested prenatally for carrier status.17 The parents are informed that their
daughters can be tested from the age of 16, because from that age onward
carrier females should be screened every 5 years for cardiomyopathy.18
However, in practice the vast majority of the girls (78%) who are beyond
the age of 16 years have not yet been tested (Figure 1). We have also
shown that one in three women at risk of carrying a mutation in DMD
families have not been tested.19 Further studies are planned to find out
why potential carriers are not tested in these families.
One might say that the young potential carriers still have time to
undergo carrier testing before having offspring as the average age for a
woman to give birth to a first child in the Netherlands is 28 years
(Statistics Netherlands, www.cbs.nl). However, that does not take into
account the risk for cardiomyopathy, which is estimated to be around
10% at the age of 50 years; the youngest described carrier with
cardiomyopathy in the Netherlands was 28 years.19,20 Furthermore, a
recent study has shown that the cardiac abnormalities in carrier women
are as progressive as in DMD patients.20 These women may not be aware
of the risk and implications of being a carrier. For some women it may
be too late as they may find out that they are carriers only after DMD is
diagnosed in a son or after experiencing (sometimes severe) cardiac
problems.21 A proactive approach of using a genetic register service to
contact the girls when they reach adulthood, as is done in the United
Kingdom,22 should be considered.
Parents in DMD families have great difficulty in communicating
with their children about the disease and its implications for the
future.23 They may struggle with the question of how to tell their
daughter that she has a risk of being a carrier. Our study has shown
that the average risk of being a carrier is 28%. So, it is cruel to subject
the parents to an ordeal, lasting years with this dilemma while the
average chance of not being a carrier is 72%. This problem could be
solved if the parents are given the choice of having their daughters
tested before adulthood at a time that is convenient for them, either
neonatally or later. In the families where fetal sexing has been done on
chorion villi or amniotic fluid and fetal DNA is available, the
possibility of carrier testing on female fetuses should be offered.







































Figure 4 The number of male fetuses per year identified by direct mutation analysis and by haplotyping for an increased risk for DMD/BMD.
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The majority of DMD patients are now the first in their family. So,
prenatal diagnosis could not have been used as a means of prevention
in these cases. Boys with a de novo mutation can only be detected if
every pregnant woman is offered a prenatal test for the DMD gene.
This is not realistic at present, but it may change in the future with
the development of effective methods of testing the fetal genome in
the maternal serum.24 The problem of de novo mutations in women
could be solved by testing every prospective mother for mutations in
the DMD gene before conception, as is now increasingly possible for
severe autosomal recessive diseases.25 However, this would require
huge investments and is perhaps something for the future. Although
prenatal screening has been used to prevent the birth of a second
affected boy in the family, this was not possible in a large number of
the cases because the older boy had not yet been diagnosed as he was
younger than 5 years. For these cases, neonatal screening would seem
the easiest solution at present.
The difficulty is that neonatal screening for an untreatable disease is
prohibited by law in the Netherlands because of the requirement that
the child in question should derive real benefit from screening. The
situation may be about to change as treatments for DMD are now in
an advanced stage of development;26–28 thus, neonatal screening may
become feasible even under the current legal restrictions. With this
expectation and the knowledge that the birth of the second affected
child can be prevented perhaps a case could be made for introducing
neonatal screening for boys sooner rather than later.
The most pressing matter for concern at present is that many girls
have not been tested. Considering the arguments given above, we
propose a change in policy, namely, that the parents should be given
the choice of having their daughters tested either prenatally if possible
or postnatally, also before adulthood when requested.
CONCLUSIONS
There was no significant change in the incidence of dystrophinopa-
thies in the Netherlands as a result of prenatal testing and genetic
counseling. However, we found evidence indicating that prenatal
testing has been used by families to prevent the birth of a second
affected boy. In the 26 years 145 male fetuses were aborted and 174
unaffected boys were born with the help of prenatal testing. Our study
has revealed two problems: (1) A high proportion of families with
de novo mutations in the DMD gene cannot make use of prenatal
diagnosis, exacerbated by the fact that older affected boys are usually
not diagnosed before the age of five; (2) Current policy dictates that
carrier testing is not done in female fetuses; the girls in DMD families
may be tested at 16 years. In practice, however, 78% of these girls who
are 16 years or older have not been tested. A carrier woman has a risk
not only of having a son with DMD but also of having progressive
cardiac disease herself. These facts, together with recent developments
that suggest DMD could become treatable in the near future, point to
an urgent need for a change in policy to improve the chances of
prevention of DMD in the future. The first is to introduce neonatal
CK screening of males and the second is to test females that are at risk
for carrier status prenatally if fetal DNA is available or postnatally
even before adulthood if requested by the parents.
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a b s t r a c t
Theoretically, 13% of patients with Duchenne muscular dystrophy may benefit from antisense-mediated
skipping of exon 51 to restore the reading frame, which results in the production of a shortened dystro-
phin protein. We give a detailed description with longitudinal follow up of three patients with Becker
muscular dystrophy with in-frame deletions in the DMD gene encompassing exon 51. Their internally
deleted, but essentially functional, dystrophins are identical to those that are expected as end products
in DMD patients treated with the exon 51 skipping therapy. The mild phenotype encourages further
development of exon 51 skipping therapy.
� 2010 Elsevier B.V. All rights reserved.
1. Introduction
Mutations in the dystrophin-encoding DMD gene on the X chro-
mosome result generally in Duchenne muscular dystrophy (DMD)
if the mutation is out-of-frame and in Becker muscular dystrophy
(BMD) if the mutation preserves the translational reading frame.
In BMD patients an altered form of dystrophin is present, whereas
in DMD patients dystrophin is virtually absent in muscle fibers.
Absence of dystrophin in a muscle biopsy has an unfavorable prog-
nosis, as DMD patients become wheelchair bound before the age of
13. The clinical phenotype in BMD is milder with a large variation
in clinical severity.
Currently, new therapeutic strategies, such as antisense-medi-
ated exon skipping, are in an early phase of clinical trials and have
the potential to change the course of the DMD disease dramati-
cally. In our recent study, intramuscular injection of an antisense
oligonucleotide (AON) induced skipping of exon 51 and restored
the disrupted open reading frame and therefore the production
of dystrophin in four DMD patients with deletions of exons 48–
50, 49–50, 50 and 52, respectively [1]. Clinical trials with systemic
administration of AON are taking place. If successful, therapeutic
skipping using an AON that targets exon 51 can stop further mus-
cle wasting, resulting in a clinical phenotype like BMD. This AON
can be applied in about 13% of the DMD patients [2]. Therefore,
focusing on the functionality of the probable end product through
studying corresponding Becker phenotypes is useful and will pro-
vide information for patients eligible for this new therapy. This
would concern the in-frame deletions of exon 45–51, 47–51, 48–
51, 49–51, 50–51, 51–52, 51–58, 51–61 and 51–63 that all are
predicted to result in a BMD phenotype.
We describe the clinical phenotype in two BMD pedigrees in the
Netherlands carrying deletions including exon 51. We also provide
a review of BMD patients with these deletions reported in the
literature.
2. Patients and methods
2.1. Methods
Since the availability of DNA diagnostics in 1984, more than
1500 Dutch DMD/BMD families have been tested in our laboratory.
The laboratory database was searched to find patients with in-
frame deletions including exon 51. After obtaining informed con-
sent, data on clinical history and neurological examinations were
extracted from clinical files and/or obtained directly from the pa-
tients by the authors (C.S. and A.H.-E.).
0960-8966/$ - see front matter � 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.nmd.2010.01.013
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Data from additional patients were collected by searching the
literature and by consulting the international DMD database at
the Leiden Muscular Dystrophy pages (http://www.DMD.nl) [3].
Where ever possible, additional information was obtained from
the authors who have published since 1993 on patients with either
a deletion of exon 45–51 or of exon 50–51 and submitted to the
database.
3. Results
3.1. Description of Dutch pedigrees
In the Dutch population we found one pedigree with a deletion
of exons 45–51 and one with a deletion of exons 50–51. Up until
February 2009 no Dutch BMD patients had been registered with
in-frame deletion of the exons 47–51, 48–51, 49–51, 51–52, 51–
58, 51–61 and 51–63.
3.1.1. Family 1: deletion exons 45–51
Patient A1, born in 1962, had suffered from painful muscle
cramps in his legs since childhood. Cramps were mostly provoked
by exercise such as hiking or occured after he had bumped his
leg. Cramps resulted in painful nodules and could last for one and
a half hour. Sometimes his father had to carry him home from
school. He did not participate in sports and did not like running.
Neurological examination at the age of 14 showed nomuscle weak-
ness. A biopsy of the quadricepsmuscle at this time showed dystro-
phic features, with groups of necrotic fibers and groups of
regenerating fibers as well as local increase of endomysial fibrous
connective tissue. In 1990 Western blotting showed a slightly re-
duced amount of dystrophin with a smaller molecular weight.
DNA analysis identified an in-frame deletion of exons 45–51 in
the DMD gene and confirmed the diagnosis of BMD. He now works
as a truck driver and rarely suffers from cramps and is not limited in
his daily activities, although he avoids jumping from his truck or
climbing more than two stairs.
In childhood he had trouble concentrating, was hyperactive and
attended a primary school for children with educational problems.
Subsequently he succeeded in obtaining a certificate from a regular
technical school.
A neurological examination in 2008 was unremarkable except
for calf hypertrophy. His creatine kinase (CK) which had increased
50-fold in 1976 was only marginally increased in 2008 (243 with a
reference value up to 200 U/l). Cardiac examination including
echocardiography showed no abnormalities. MRI showed normal
aspect of the shoulder muscles and the muscles of the leg. There
were minimal fatty changes in the hip extensors (Fig. 1).
His maternal grandfather (patient A2), born 1913 and deceased
1993, carried the same mutation. He too had suffered from cramps
in childhood and adolescence. At the age of 78 he was examined by
the late Prof. HFM Busch, neurologist. The grandfather showed no
neurological signs or symptoms of BMD and his CK values were
normal.
3.1.2. Family 2: deletion exons 50–51
Patient B1, born in 1994, visited a pediatrician at the age of 8 be-
cause of hyperactive behavior. His past history was unremarkable
including normal motor milestones; he was able to walk unsup-
ported at the age of 18 months. Routine laboratory examination re-
vealed increased transaminases and subsequently 8-fold increase in
CK.Neurological examination in 2003was unremarkable. DNAanal-
ysis showed an in-frame deletion of exons 50–51 in the DMD gene.
In 2008 he sporadically suffered from muscle cramps but did
not complain about muscle weakness. He cycled to school every
day for more than an hour each way, including riding uphill. He en-
joyed climbing trees to help with pruning the branches, and played
in a soccer team. Neurological examination showed normal muscle
strength. There was no calf hypertrophy. ECG and echocardiogra-
phy were normal. His mean time on a timed run test of 10 m
was 2.6 s, (reference: mean time to run 9 m for healthy boys of
11 years is 2.5 ± 0.28 s) [4].
Behavior problems were diagnosed as attention deficit hyperac-
tivity disorder (ADHD) by a child psychiatrist. Cognitive tests
showed a subnormal IQ of 80 with performance IQ lower (77) than
verbal IQ (90). For hyperactivity he was treated with methylpheni-
date (Ritalin) 54 mg/day, 5 days a week. He attended a primary
school for special education. He now follows regular secondary
education. He is still hyperactive during the weekend when he is
off methylphenidate.
His mother carries the same BMD mutation. He has a healthy
brother, born 1992, who has not been tested.
3.2. Patients from the DMD database at the Leiden Muscular
Dystrophy pages and from published reports
The DMD gene variant database at the ‘‘LeidenMuscular Dystro-
phypages, http://www.DMD.nl” [3] is a public repository of variants
reported in literature or submitted directly to the database.Weused
Fig. 1. MRI images of the muscles in patient A1. MRI axial T1-weighted images of the muscles in patient A1 at age 46 shows at the level of (A) the shoulder: normal volume
and signal intensity of the muscles, (B) the hip joint: minimal fatty changes in the gluteal muscles (arrows), (C) upper leg: normal volume and signal intensity of the muscles
and (D) lower leg: normal volume and signal intensity of the muscles.
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this valuable resource to trace 57 patients with a deletion of exons
45–51 or 50–51, including our three patients. On February 3rd
2009 the DMD database listed 27 entries with a deletion of exons
45–51 (including50patients) andsixentrieswithadeletionofexons
50–51(7patients); 21of the33 submissionswere frompublished re-
ports. After contacting the authors, six patients were excluded for
further analysis; in two patients further testing with MLPA (Multi-
plex Ligation-dependant ProbeAmplification) refined themutations
originally detected by PCR to deletions of exons 45–54 and 49–51.
One submitter reported that two patients could not be traced back
in his database. Furthermore, two patients were excluded because
they appeared to have a Duchenne phenotype; their genotype was
tested with multiplex-PCR and might be not reliable enough. One
submission appeared to be a monozygotic twin. All new findings
were reported to the DMD database and used to update the records.
In summary, 50 patients were traced using the information in the
DMD gene variant database.
Our literature search identified six more patients with deletions
of exons 45–51 [5–7] and six more patients with deletion exons
50–51 in the literature [8,9].
We made an overview of the 19 patients of whom we obtained
clinical information (Tables 1 and 2). These 19 BMD patients came
from 12 families. For 43 patients no further information was
available.
4. Discussion
Our study shows that BMD patients with 45–51 or 50–51 in-
frame mutations have a mild phenotype.
The clinical phenotype of the three Dutch patients, including
the grandfather shows certain similarities. The course of the dis-
ease is mild with muscle cramps without muscle weakness and hy-
per-CK-emia being the main features. As adults these patients
showed no clear evidence of progression of the disease with age.
None of the patients experienced major limitations in daily life.
Intolerance to exercise appears to restrict patient A1. Although
both patients A1and B1 have had behavioral or attention problems
at primary school, they attended regular secondary school and pa-
tient A1 functions normally as an adult. Behavioral and attention
Table 1





























78 78 Cramps Normal M-PCR Patient A2 present
study
A3 "CK 5 5 Contractures, mild proximal muscle









7 7 No 896 Normal [6]
A6 Grandfather
patient A4
67 67 No 63 Normal [6]
A7 Pain on
exercise
8 8 Pain, mild calf hypertrophy 1000 Normal M-PCR Dystrophin
present
[21]
A8 "CK 10 11 No M-PCR Dystrophin
present
[5] patient B-19
A9 Myoglobinuria 14 14 No M-PCR Dystrophin
present
[5] patient B-25
A10 10 2648 M-PCR DMD database
P.J.Taylor




A12 "CK 4 16 No 810 Normal M-PCR Dystrophin
present
[22]
Abbreviations used: MLPA, Multiplex Ligation-dependant Probe Amplification; M-PCR, Multiplex Polymerase Chain Reaction; CK, Creatine Kinase.
Table 2
BMD patients with a deletion of exons 50–51.
Patient
number




















B2 Limping falling 2 4 Yes 1300 Normal M-PCR Dystrophin
present
[8]
B3 Grandfather patient B2 69 69 No Normal M-PCR [8]
B4 Great uncle of patient B2 55 55 No M-PCR [8]
B5 Cousin of mother of patient B2 28 28 No M-PCR [8]
B6 Maternal cousin mother of
patient B2
29–55 29–55 No M-PCR [8]
B7 Maternal cousin DMD patient
with another mutation
18 18 No 327 M-PCR Dystrophin
present
[9]
Abbreviations used: MLPA, Multiplex Ligation-dependant Probe Amplification; M-PCR, Multiplex Polymerase Chain Reaction; CK, Creatine Kinase.
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problems appear to occur more frequently in boys with Becker
muscular dystrophy than in the general population [10].
Also the patients reported in the literature had a mild course of
the disease. At older age they did not show any symptoms of BMD
and had a normal result of cardiac examination [6,8].The low prev-
alence of known in-frame mutations encompassing exon 51 in the
Dutch population could well be an underestimation. Patients with
a comparable mild phenotype as the ones we have described might
not have been recognized as a possible BMD and may never have
visited a neurologist or a pediatrician.
Our study clearly shows that previous publications are not
always correct regarding the extent of the deletions reported. Until
recently deletions were mainly detected using methods like South-
ern blotting, multiplex-PCR (Chamberlain and Beggs sets [11,12]
and quantitative multiplex-PCR. MLPA [13] is much more accurate
and ideally should be used to confirm the deletions and, more
importantly regarding clinical outcome, to reliably determine its
boundaries. Furthermore, only analysis at RNA level will be able
to confirm that the translational reading frame remains intact.
It should be noted that the public availability of the DMD data-
base was an enormous help for our study. It gave a clear overview
of the findings thus far and an easy resource to contact the groups
having patients of interest. Of course it is unfortunate that not all
data reported are correct, but the database itself is not to blame
for this. To support the database we immediately reported addi-
tions and inconsistencies for inclusion or correction.
Gathering information about the phenotype of BMD patients
has become relevant now that exon skipping therapies are being
developed for DMD patients. Since exon skipping is mutation spe-
cific, each specific exon skip will result in a different shortened var-
iant of dystrophin. Therefore, information on the best target exon
for individual DMD patients may be found by examining BMD
patients with different dystrophin variants. Since the first clinical
trials are aimed at skipping exon 51, we have focused on BMD
patients with a mutation encompassing this region. In fact, one
of the DMD patients that was treated in the first human exon skip-
ping trial [1] had a deletion of exon 50. After local treatment with
antisense PRO051 the reading frame was restored and he produced
dystrophin which should be similar to the dystrophin of patient B1
in our study. This demonstrates how one exon made the difference
of being wheelchair bound at age 9 or climbing trees at age 14. The
ultimate goal is to develop specific treatments to restore dystro-
phin production in DMD patients.
Besides, it is important to realize that these findings are muta-
tion specific as a smaller in-frame deletion in this same area, such
as a deletion of exons 48–49, results in X-linked dilated cardiomy-
opathy [14]. Also the in-frame deletions of exon 51–61 and 51–63
will most probably result in a moderate to severe phenotype,
because they are close to the cysteine rich region (exon 64–70)
which might affect the binding of dystrophin to b-dystroglycan
[15]. Mice with a deletion of such a cysteine rich region have mus-
cles with severe dystrophic pathology [16]. Furthermore, a deletion
of exons 45–55 is associated with a BMD phenotype with a progno-
sis of a favorable outcome [17], but can also be associated with
X-linked dilated cardiomyopathy depending on the exact location
of the breakpoints of the deletion [18,19].
Given the many different mutations, patients will benefit highly
of multidisciplinary cooperation that results in databases with
information on genotype as well as on phenotype [20]. For the dys-
trophinopathies good databases will facilitate and accelerate the
inclusion of patients in clinical trials. This underlines the impor-
tance of setting up national patient registries, which can contribute
to an international database. A good example of such a database is
the TREAT NMD network of excellence (http://www.treat-nmd.eu/
home.php).
In conclusion, the phenotype of BMD patients with a deletion of
exons 45–51 and 50–51 appears to be mild. This is encouraging for
the outcome of the exon 51 skipping trials and offers hope to DMD
patients who are eligible for this therapy.
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Chapter 6  Summary, discussion and future prospects
6.1  Summary and discussion
Dystrophinopathies include the well known Duchenne muscular dystrophy (DMD) and Becker 
muscular dystrophy (BMD). The incidence of DMD, which is a progressive neuromuscular 
disease, is roughly 1 in 3,500 live male births (Emery, 1991), in the Netherlands 1 in 4685 
(Helderman-van der Enden et al., 2012). Most of the patients are diagnosed around the age 
of five (Magri et al., 2011) and are wheelchair-bound before the age of 13. The mean age of 
survival is 25 (Eagle et al., 2002). The incidence of BMD, a milder variant of DMD, is 1 in 
18,450 live male births (Bushby et al., 1991). The onset of BMD is usually between the ages 
of 5 and 15 but may also be later (Bushby and Gardner-Medwin, 1993). Dystrophinopathies 
show an X-linked recessive pattern of inheritance. Mutations in the DMD gene generally 
lead to DMD if the mutation is out-of-frame and to BMD if the translation reading frame is 
preserved (Malhotra et al., 1988; Monaco et al., 1988).
This thesis is a collection of several clinical and genetic studies on dystrophinopathies with 
implications for genetic counselling of patients and their families and for future therapy (e.g. 
personalized medicine) of patients suffering from this group of chronic progressive muscle 
diseases.
6.1.1  Mosaicism
6.1.1.1  Germ line mosaicism
Different frequencies have been reported for germ line mosaicism in DMD. A reliable 
estimate of the recurrence risk of new mutations, obtained preferably by empiric studies of 
large numbers of families, is important for genetic counselling.
In Chapter 2.1 we have described the largest number of dystrophinopathy families known 
to date with a de novo mutation. Germ line mosaicism is an important pitfall that should be 
considered when counselling families with a de novo mutation. 
A literature search on germ line mosaicism revealed that an estimate for the recurrence 
risk has been calculated for only seven out of 63 diseases with documented germ line 
mosaicism. Two are autosomal dominant, with a risk of 0.02% for achondroplasia (Mettler 
and Fraser, 2000) and 5-7% for osteogenesis imperfecta (Byers et al., 1988). The other five 
are X-linked. The risk is 11% for double cortex X-linked lissencephaly syndrome (Gleeson 
et al., 2000), for RETT syndrome (Mari et al., 2005), and for haemophilia B (Ketterling 
et al., 1999) and 13% for haemophilia A (Leuer et al., 2001). Until recently the reported 
recurrence risk for DMD, if the risk haplotype is transmitted, varied from 14 to 20% (Bakker 
et al., 1989; van Essen et al., 1992). It is remarkable that the recurrence risk is reported 
more often for X-linked inherited diseases and that the risk for these diseases is higher. 
Most reported recurrence risks are expressed as the percentage of de novo families that 
have germ line mosaicism. To obtain a more reliable recurrence risk in our DMD families 
we divided the number of times the risk haplotype was transmitted with the mutation by 
the total number of times that the risk haplotype has been transmitted (with or without the 
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of 8.6% (95% confidence interval 4.8 – 12.2%) if the risk haplotype is transmitted. In de 
novo DMD/BMD families that have not been haplotyped the recurrence risk is 4.3%.
Factors that could influence the recurrence risk in germ line mosaicism 
Origin of the mutation: 
In the 18 proven germ line mosaicism families in our study most mutations, 14/18 (78%) 
originated in the mother and the remaining 4/18 (22%) in a grandparent (all four in the 
grandmother). These percentages are comparable to those found in the whole group of 
318 families with a de novo mutation (73% maternal, 27% grandparental). Of the 86 in the 
grandparental group, 40 occurred in the grandmother, 27 in the grandfather and in 19, the 
origin could not be determined. We conclude that the number of de novo families with proven 
germ line mosaicism in our study is too small to determine whether the origin of the mutation 
has any influence on  the recurrence risk in germ line mosaicism. 
Type and location of the mutation:
Among the families with proven germ line mutations, 14/18 were deletions (77%), 3/18 were 
duplications (17%) and 1/18 was a point mutation (6%). The percentage of deletions and 
duplications are comparable to the expected ratio of mutations in the DMD gene, i.e. 72% 
deletions and 7% duplications, but the number of point mutations is smaller than the expected 
~20%. The number of proven germ line mutations in our study group is too small to draw 
any definite conclusion as to whether the type of mutation can influence the recurrence risk 
in germ line mosaicism.
There was a remarkable difference in the recurrence risk between deletions that were located 
proximally (7.8%) and those that were distally located (3.2%). It has been speculated that 
proximal deletions arise earlier in embryogenesis than distal ones and are therefore more 
likely to be found also in germ cells. (Passosbueno et al.,1992). The recurrence risk is 6.1% 
for duplications and 2.2% for point mutations. It appears, therefore, that the location of the 
mutation may play a role in the recurrence risk in germ line mosaicism. 
The percentage of de novo cases: 
The rate of new mutations for DMD is 33% and the recurrence risk in cases of germ line mosaicism 
is 4.3%. On the other hand, achondroplasia is de novo in 80% of cases whereas the recurrence 
risk due to germ line mosaicism (0.02 %) is very low (Mettler and Fraser, 2000). There appears 
to be no association between a high percentage of de novo cases and a high germ line recurrence 
risk. The de novo mutations in case of achondroplasia are apparently a result of de novo events 
during spermatogenesis in the unaffected father rather than of germ line mosaicism in the father 
(Francomano, 2006). It is possible that one of the factors that influence the recurrence risk due to 
germ line mosaicism is the proneness of the gene to undergo mutations. 
In general, we conclude that more studies are needed to elucidate the factors that influence the 
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6.1.1.2  Somatic mosaicism
A mutation in one of mitotic divisions of the zygote can give rise to somatic mosaicism 
in the patient. In Chapter 2.2, we have presented a 30-year old ambulatory patient with 
somatic mosaicism. The first indication that we may be dealing with mosaicism came from 
the immunohistochemical dystrophin analysis of the muscle biopsy, which showed a mixture 
of dystrophin positive and dystrophin negative fibres. DNA analysis revealed a nonsense 
mutation (c.9554C>T, pQ3116X) in the DMD gene. This mutation is described as c.9346C>T, 
p.Gln3116X according to the new nomenclature. It disrupts the reading frame which would 
normally lead to full DMD, but the phenotype of the man was milder. We considered BMD 
because of the mild phenotype but excluded it because patients with BMD have progressive 
symmetrical muscular weakness and contractures appear later, namely when patients become 
wheelchair-bound. Our patient had asymmetric weakness and prominent contractures 
while he was still ambulant. In fact, the mild phenotype of our patient was due to somatic 
mosaicism. To our knowledge, only two cases with somatic mosaicism of the DMD gene 
have been reported since our case was published, indicating that patients who show clinical 
manifestation of somatic mosaicism are rare (Deburgrave et al., 2007; Kesari et al., 2009).
6.1.2  Dystrophinopathy in the family: have potential carriers been tested?
In Chapter 3, we have shown that even in the Netherlands with its well-organized genetic 
counselling services, there are still a large number of potential carrier women in DMD/BMD 
families who have not been tested at the DNA level. In the DMD families that were analyzed, 
55% of the women with a 50% risk of being a carrier and 43% of the women with 4.3% risk 
due to germ line mosaicism had not been tested. In general, it is agreed that carrier testing 
in minors should be deferred until the child can give proper informed consent (Borry et al., 
2006). However, even if we consider only women older than 16, 34% with a 50% risk and 
30% with a germ line risk had not been tested. Therefore, one in three potential adult carriers 
(sisters and or maternal aunts) in DMD families has not had a DNA test. 
Given the possible far-reaching clinical consequences of being a carrier, we have planned 
further studies to investigate the reasons why potential female carriers have not been tested. 
6.1.3  An urgent need for a change in policy revealed by a study on prenatal testing 
for Duchenne muscular dystrophy 
In Chapter 4, we have examined the impact of 26 years of prenatal testing for Duchenne and 
Becker Muscular Dystrophy in the Netherlands. We analysed information on all prenatal 
diagnoses performed from 1984 to 2009. Of the 635 prenatal diagnoses performed in this 
period, 51% were males. Of these, nearly half (46%) were affected or had an increased risk 
of having DMD/BMD. As a result, 145 male foetuses were aborted and 174 unaffected boys 
were born. The most significant positive effect of prenatal testing was the birth of these 174 
unaffected boys. The introduction of prenatal testing for the familial mutation has spared the 
parents the emotional burden of having to abort a possibly healthy boy. For a few families 
pre-implantation genetic diagnosis offered the possibility of having children without the 
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To determine the impact of prenatal testing on the incidence of DMD, we compared the 
incidence in the sixties to that in the nineties. There was no significant difference in incidence 
of DMD between the first (1961-1974) and the second period (1993-2002). We did find, 
however, that the percentage of first affected boys in the DMD families increased from 62% 
in the first period to 88% in the second period, 1993-2002. These figures show that although 
there was no apparent decrease in the incidence of the disease, prenatal diagnosis was used 
by DMD families for preventing the birth of a second affected boy. 
Women who do not have an increased risk of being a carrier are not offered the possibility of 
prenatal testing for a dystrophinopathy. This applies to de novo families. It has been always 
assumed that one in three DMD patients has a de novo mutation (Haldane, 1935). In fact, this 
figure of 33% may be an underestimate and the real figure may be as high as 57% (Alcantara 
et al., 1999; Taylor, 2008). Perhaps this discrepancy can be explained by the fact that in the 
last decades, the families are smaller and family planning and prenatal testing are possible.
However, even if we say that the risk is 33%, the final figure of de novo cases is a lot higher 
if we consider the whole family. The mutation is de novo not only in 1/3 of the patients but 
also in 1/3 of carrier mothers. In theory, the total number of DMD patients who are the first 
affected in the family is at least 56% (1/3 de novo in the patient plus 1/3 x 2/3 de novo in 
the carrier mother). This means that a large proportion of families are unable to make use of 
prenatal diagnosis to prevent the birth of an affected son because the mutation has occurred 
de novo. In our study of 216 boys with DMD, born in the period 1993-2002, prenatal testing 
was not an option in 88% of these as they were the first affected in the family. However, it 
was also not an option for most of the remaining 12% because information about DMD in the 
older boy was not available at the time of the birth; in almost half of these, the older boy was 
less than five years old at the time of the birth of the second boy. 
Women with a de novo mutation can be identified if every woman is tested pre-conceptionally 
for dystrophinopathy, as is now possible for a number of autosomal recessive diseases (Bell 
et al., 2011). Boys with a de novo mutation can only be detected if every pregnant woman 
is given a prenatal test. This is not realistic at present, but it may change in the future with 
the development of effective methods for testing the foetal genome in maternal serum (Lo 
et al., 2010).
Another important finding in our study is that 78% of the females, who were prenatally 
identified as potential carriers and who at the end of our study period (2009) would have been 
between 16 and 26 years of age, have not yet been tested for carrier status.
In short, our study has revealed that 1) a high proportion of families with de novo mutations in 
the DMD gene cannot make use of prenatal diagnosis, partly because the older affected boys 
are diagnosed at around five years, and 2) a large proportion of female potential carriers have 
not been tested. One can expect that there are a multitude of different obstacles hampering the 
cascade screening of DMD families, and the testing of potential carriers following prenatal 
diagnosis. At present, we do not know the most important impediments and how they can be 
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that 1) neonatal screening for dystrophinopathy in males should be started in the Netherlands 
and 2) parents should be given the choice of having their daughters tested prenatally, in cases 
where foetal sexing has been done on amniotic fluid or chorionic villi, or postnatally, even 
before adulthood.
6.1.4  Becker muscular dystrophy patients with deletions around exon 51. 
Chapter 5 zooms in on exciting developments in the field of personalized medicine for 
Duchenne muscular dystrophy. Theoretically, 83% of patients with DMD may benefit from 
exon skipping therapy, which can restore the reading frame in the patient (see 6.1 above) 
(Aartsma-Rus et al., 2009). Antisense-mediated skipping of exon 51 restores the reading 
frame and results in the production of a shortened dystrophin protein (Aartsma-Rus et al., 
2009). We have given a detailed description of a longitudinal follow up of three patients 
with Becker muscular dystrophy with in-frame deletions encompassing exon 51 in the DMD 
gene. The internally deleted, but essentially functional, dystrophins in these BMD patients 
are identical to those that are expected as end products in DMD patients treated with the exon 
51 skipping therapy. The mild phenotype of the three described patients encourages further 
development of exon 51 skipping therapy. One of our patients is included in an international 
follow-up study of quantification of dystrophin in 17 BMD patients with deletions around 
exon 51. The results indicate that the three types of internally deleted dystrophins assessed 
in the study have the functional capability of providing a substantial clinical benefit to DMD 
patients (Anthony et al., 2011). 
6.2  Future prospects
At present, the most common dystrophinopathies are still serious life-shortening diseases for 
which curative therapy is not yet available. Therefore, much emphasis has been placed on 
prevention. This is only possible through adequate genetic counselling and prenatal testing 
of known families. 
In this thesis (see 6.1.2 and 6.1.3 above) we have shown that we need to address two points: 
1) early detection of boys with DMD caused by de novo mutations with a view to preventing 
the birth of subsequent affected boys in the family and also for possible therapy in the future 
(see 6.2.1 below). 2) DNA testing of potential carriers (see 6.2.2 below).
6.2.1  Early detection of de novo DMD boys: neonatal population screening for 
dystrophinopathy
We have shown (see 6.1.3 above) that the birth of a second affected boy could have been 
prevented if DMD had been diagnosed early in an older affected boy in the family. The 
percentage of boys with an older affected relative varies in the literature: for example 13% 
(16/122) in North-East England (Gardner-Medwin et al., 1978) and 33% (61/181) in Iowa 
(Zellweger et al., 1982). In our cohort of 216 boys born between 1993 and 2002, the birth of 
27 affected boys (12%) could have been prevented by means of prenatal testing if the older 
affected boy had been detected by neonatal screening. 
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child at the time of testing (preventive surgery or early therapeutic intervention) (Borry et 
al., 2008). Although prospective parents in the Dutch population seem to be interested in 
neonatal screening for untreatable childhood-onset disorders (Plass et al., 2010), DMD is 
not included in the neonatal screening program in the Netherlands at present. This is because 
so far it is considered to be a non-treatable disease (The Dutch Health Council: Neonatal 
Screening, 2005). We expect that with developments in personalized medicine, such as exon 
skipping therapy (Aartsma-Rus, 2010; Goemans et al., 2011; Guglieri and Bushby, 2010; Van 
Deutekom et al., 2007), the options for early treatment of dystrophinopathies will become 
available in the near future. If that happens, early diagnosis will become essential also for 
the patient. 
While preparing this thesis, we counselled a Dutch family with a history that illustrates 
the importance of neonatal screening for the prevention of the birth of subsequent affected 
children in a family. 
 
      
The first patient was born in 1995 but it was only in 2002, at the age of seven, that DMD was 
diagnosed; the delay was due to other health problems.
After his diagnosis, it became clear that one of his younger brothers and a cousin, both 
born in 2000, were also affected. In 2003, some months after the diagnosis of the index 
patient, another affected cousin was born in the family. According to their respective parents 
(personal communications) if the index patient had been diagnosed by neonatal screening the 
three subsequent affected boys would most probably not have been born. 
A questionnaire among Dutch Duchenne families showed that most parents are in favour of 
neonatal screening. All the parents wished they had known the diagnosis earlier, preferably 
before the child was two years of age. They regretted having treated their child the way 
they did during the period in which they were unaware of his disorder. Early diagnosis 
would have enabled parents to treat their child in a way most suited to his condition (‘good 
parenting’). This need for ‘good parenting’ expressed by the parents by far outweighed the 
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Figure 1:
Pedigree of a Dutch family illustrating the importance of neonatal screening for the prevention of the 
birth of subsequent affected children (with the kind permission of the family). 
      male,        female,        affected male,        carrier female
Table 1 shows the published results from neonatal screening for dystrophinopathies in various 
countries (including those where a pilot has been performed); the percentage of affected 
neonates is very similar.
In 2004 a working group of experts in the field of neonatal screening and dystrophinopathies 
met in Atlanta, USA and agreed on the following key points about newborn screening for 
DMD (Newborn Screening for Duchenne Muscular Dystrophy Workgroup: Lay Report, 
2004): 
• An earlier age at diagnosis of DMD might improve the quality of life of families. 
• There are no universal early signs or symptoms by which all children with DMD can be 
recognized by paediatricians at an early age. 
• The current newborn screening standards do not justify mandatory newborn screening for 
DMD given the lack of evidence of medical benefit to the child. 
• Voluntary newborn screening for DMD, as a supplement to mandatory newborn screening 
programs, might be problematic because (1) the period immediately before or after birth 
is a difficult time to obtain true informed consent, and (2) parents might have trouble 
distinguishing voluntary testing for DMD from other mandatory newborn screening 
tests. 
• Mandatory and voluntary newborn screening tests ideally should be separated in time and 
space. 
• False or transient-positive screening results might have a negative impact on families. 





















































(Eyskens and Philips, 2006)
(Scheuerbrandt, 2011)
(Al-Dahhak et al., 2008)
(Meeting discusses newborn screening for 
Duchenne muscular dystrophy, 2011)
(Drousiotou et al., 1998)
(Greenberg et al., 1988)
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• Screening later in infancy might introduce inequities into the system because not all 
families have equal access to routine paediatric services. 
• Identification of appropriate personnel and protocols for informing parents of test results 
is critical. 
It is important that the parents should be informed about the pros and cons of testing in a 
manner that is analogous to antenatal screening: so that a decision can be made without any 
feelings of obligation (Plass, 2007).
In principle, the CK screening test could also be offered for female newborns because some 
female carriers have a high CK. If the CK is high, molecular testing can be done to detect 
a mutation and to confirm that the girl is a carrier. In this way girls who are carriers of a de 
novo mutation or who have inherited the mutation from a mother who was unaware of being 
a carrier, can be identified. The birth of affected boys in these families can be prevented with 
the help of genetic counselling. However, we need more studies before we can introduce 
neonatal screening for the detection of carrier status in females, since not all carriers are 
picked up with the CK screening test. Furthermore, it is not possible as yet to predict whether 
a female carrier will develop any symptoms (Newborn Screening for Duchenne Muscular 
Dystrophy Workgroup: Lay Report, 2004).
In any case, testing for dystrophinopathies in newborn boys on a voluntary basis could start 
as soon as possible in the Netherlands.
6.2.2  DNA testing of potential carriers in known families 
We have shown that a high proportion of women who are potential carriers have not been 
tested to determine whether they are carriers or not. These are adult family members of 
affected males (Chapter 3) or women who were identified prenatally and are now 16 years or 
older (Chapter 4). It is important to test potential carriers and to inform them of their risk of 
having an affected son as well as the risk of developing heart problems themselves. A study 
in the United Kingdom among 33 families with six different genetic diseases has shown 
that children with DMD receive less information than those with other diseases and that 
the daughters in the DMD families are not informed about potential carrier risk until they 
are about 16. The parents of DMD patients carry a heavy burden of having to inform their 
children, which can be difficult and stressful (Plumridge et al., 2010). 
Early testing of potential carriers would greatly reduce the anxiety of parents. We have shown 
that the average risk of a girl in a DMD family being a carrier is 28% (Helderman-van den 
Enden et al., 2012). This means that almost three-quarters of the parents struggle for nearly 
two decades with the dilemma of how best to tell their daughter, while the chance that she 
is not a carrier is 72%. The problem could be avoided if the parents are given the choice 
of having their daughters tested before adulthood. Also, families with a daughter who is a 
carrier will probably be able to prepare themselves better, both emotionally and practically, 
for informing their daughters (Campbell and Ross, 2005).
In current practice, the consensus on not testing minors (see 6.2.1 above) also holds for carrier 
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the age of 16, carrier testing of girls at this age is logical (Bushby et al., 2003; Hermans et 
al., 2010). In the absence of compelling reasons, therefore, carrier testing is deferred until 
adulthood when the person can give informed consent. 
Incidentally obtained genetic information
According to two guidelines on genetic testing, information on carrier status obtained 
incidentally (e.g., after screening or prenatal diagnosis) should not be disclosed to parents 
or to third parties (American Medical Association: genetic testing of childeren, 1995; 
Committee for Public Relations and Ethical Issues of the German Society of Human Genetics: 
Statement on Genetic Diagnosis in Children and Adolescents, 1995). They recommend that 
this information should be discussed with the child when he or she reaches reproductive age. 
This is in contradiction with the recommendations made by the British Medical Association 
(British Medical Association.Human Genetics: Choice and Responsibility, 1998) and by the 
American Academy of Pediatrics (Committee on Bioethics, 2001), which state that results 
obtained incidentally on the carrier status should be conveyed to the parents. 
At present, with the introduction of DNA tests in neonatal screening, the doctors are 
frequently confronted with incidentally obtained results. Some couples may find themselves 
in a difficult situation because of the above-mentioned contradictory policies. For example 
a couple may receive information about the carrier status of one child following neonatal 
screening, but are counselled to delay carrier testing for another child until this child has 
reached reproductive age (Borry et al., 2007). These situations illustrate the importance of a 
uniform way of handling. 
On the one hand the parents are responsible for discussing the possibilities of carrier testing 
with their children and on the other hand genetic service providers are supposed to follow 
up the genetic risk of a family. This could lead to situations where a minor is never informed 
about his/her genetic risk. Borry et al (2006) emphasize that such situations should be avoided 
but do not suggest how this should be done. 
We suggest that when counselling anyone from a known dystrophinopathy family the 
possibility of other eligible members for counselling and carrier testing should be discussed. 
Genetic counsellors should re-contact the family every few years to discuss these possibilities. 
The parents and their potential carrier daughters should be informed about the pros and cons 
of testing before adulthood. 
6.2.3  Recommendations
• Testing for dystrophinopathies in newborn boys on a voluntary basis should start as soon as 
possible in the Netherlands. This will reduce the chance of the birth of subsequent affected 
boys in the family and will also help in early introduction of possible therapy when this 
becomes available.
• Parents should be given the choice of having their daughters tested prenatally, if foetal DNA 
is available. They should also be encouraged to have their daughters tested, even before 
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the burden for the parents who have to inform their daughter of their future risks.
• Genetic counsellors should have a more active approach to cascade screening and informing 
the patients and their families of their risks and possibilities.
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6.3  Samenvatting
Dystrofinopathieën zijn geslachtsgebonden erfelijke spierziekten die veroorzaakt worden 
door mutaties in het DMD gen. Dit gen codeert voor het spiereiwit dystrofine.
Voornamelijk jongens/mannen zijn ziek omdat zij maar één kopie hebben van het DMD gen 
op het X-chromosoom. Vrouwen hebben twee X-chromosomen met elk een DMD gen. Een 
mutatie in één van de twee genen geeft meestal geen klachten, omdat er nog een normaal gen 
aanwezig is. 
De meest bekende dystrofinopathie is Duchenne spierdystrofie (DMD). De ziekte komt voor 
bij 1 op 4685 pasgeboren jongens in Nederland. Jongens met deze ziekte missen het eiwit 
dystrofine in hun spiercellen. Meestal wordt dit veroorzaakt door een leesraam-verschuivende 
mutatie in het DMD gen, waardoor er geen of nauwelijks dystrofine wordt gesynthetiseerd. 
De eerste tekenen uiten zich soms al voor de leeftijd van twee jaar in de vorm van laat gaan 
lopen, de neiging om op de tenen te lopen en vaak vallen. Bij de meeste patiënten wordt 
de diagnose gesteld rond het vijfde jaar. Opvallend is de kuithypertrofie. Er is toenemende 
symmetrische spierzwakte waardoor patiënten voor het 12e jaar rolstoelafhankelijk worden. 
De ziekte is momenteel niet te genezen. Met de huidige behandeling is de gemiddelde 
levensverwachting ongeveer dertig jaar. Patiënten overlijden aan de gevolgen van niet goed 
kunnen ademen (door aangedane ademhalingspieren) en/of een niet goed pompend hart.
Becker spierdystrofie is ook een dystrofinopathie. De ziekte heeft een milder beloop dan 
DMD. Becker patiënten worden per definitie niet rolstoelgebonden voor het 16e jaar en een 
groot aantal van hen komt ook nooit in een rolstoel terecht. Wel kunnen zij hartklachten 
krijgen zoals bij DMD. Soms treden de hartklachten zelfs meer op de voorgrond dan de 
spierzwakte.
In de spiercellen van Becker patiënten is wel (gedeeltelijk) functioneel dystrofine aanwezig, 
maar meestal is het dystrofine eiwit kleiner dan normaal en in kleinere hoeveelheden aanwezig. 
In de regel wordt dit veroorzaakt door een mutatie in het DMD gen die het leesraam intact laat. 
Vrouwen die draagster zijn van een mutatie in het DMD gen krijgen meestal geen 
spierklachten. Wel hebben zij een kans van 10% om gedurende het leven hartklachten 
te ontwikkelen. Om die reden komen zij in aanmerking voor regelmatige cardiologische 
controles vanaf de leeftijd van 16 jaar. 
In dit proefschrift worden een aantal studies beschreven die van belang zijn voor het geven 
van erfelijkheidsadvies aan patiënten en hun familieleden en één studie die relevant is voor 
de naar verwachting op niet al te lange termijn in te voeren exon skipping therapie.
Mozaïcisme
Kiemcelmozaïcisme
Kiemcellen zijn geslachtscellen, zaadcellen bij de man en eicellen bij de vrouw. Bij 
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geslachtscellen en geslachtscellen met een mutatie. Indien een geslachtscel met een mutatie 
bevrucht wordt, kan de bevruchte eicel uitgroeien tot een kind met een erfelijke ziekte.
De kans voor elke vrouw op een zoon met DMD is ongeveer 1 op 10.000, terwijl de kans op 
een DMD zoon voor een vrouw die draagster is van een mutatie in het DMD gen 50% is. Bij 
ongeveer een derde tot de helft van de Duchenne patiënten is de ziekte ontstaan als gevolg 
van een nieuwe mutatie in het X-chromosoom in de eicel van de moeder. De moeder is dan 
geen draagster van deze mutatie in haar bloedcellen. Soms blijkt dat zij wel meerdere eicellen 
heeft met deze mutatie naast normale eicellen zonder de mutatie. Voor de groep vrouwen met 
een zoon met een nieuw ontstane mutatie, is de kans op een tweede zoon met Duchenne hoger 
dan het populatie risico. In 1989 werd in 28 Nederlandse families met een nieuwe mutatie 
berekend dat de kans om de mutatie een tweede keer door te geven ongeveer 7% was. 
In hoofdstuk 2.1 wordt de grootste groep dystrofinopathie patiënten uit 318 verschillende 
families beschreven bij wie de mutatie nieuw is ontstaan. Hierdoor was het mogelijk om de 
kans voor een niet-draagster moeder op een tweede zoon met DMD te berekenen: 4,3%. Dit 
percentage heeft een kleiner betrouwbaarheidsinterval dan eerdere percentages en kan sinds 
de publicatie van dit artikel in 2009, gebruikt worden bij het geven van erfelijkheidsadvies 
in deze families.
Somatisch mozaïcisme
Somatisch mozaïcisme betekent dat in een deel van de lichaamscellen van een persoon een 
mutatie aanwezig is, terwijl de overige cellen normaal zijn. In hoofdstuk 2.2 beschrijven 
we een 30-jarige man met een dystrofinopathie veroorzaakt door een somatisch mozaïcisme. 
De eerste aanwijzing voor het somatisch mozaïcisme was de observatie van spiervezels 
met en zonder dystrofine in zijn spierbiopt. Daarna toonde DNA-onderzoek een leesraam-
verschuivende mutatie in het DMD gen in een deel van zijn cellen aan. Deze mutatie zou 
normaliter leiden tot DMD. De patiënt had echter een veel milder klinisch beeld. Het 
beeld paste evenmin bij Becker spierdystrofie omdat daar symmetrische spierzwakte en 
contracturen ontstaan op het moment dat patiënten rolstoelgebonden raken. Onze patiënt had 
asymmetrische spierzwakte en contracturen terwijl hij nog ambulant was. 
Zijn relatief milde ziektebeeld bleek verklaard te kunnen worden door somatisch mozaïcisme. 
Na de publicatie van onze patiënt in 2003 zijn er, voor zover wij konden nagaan, slechts twee 
andere patiënten met somatisch mozaïcisme in het DMD gen beschreven, beiden in 2007. 
Patiënten met klachten veroorzaakt door somatisch mozaïcisme in dit gen zijn zeldzaam.
Duchenne/Becker spierdystrofie in de familie, zijn vrouwen getest met behulp 
van DNA-onderzoek?
In hoofdstuk 3 beschrijven we dat, ondanks de aanwezigheid van acht klinisch genetische 
centra in een relatief klein land, een groot aantal vrouwen uit Nederlandse Duchenne/Becker 
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De onderzochte vrouwen in deze studie zijn zussen van patiënten en zussen van de moeders van 
patiënten. Uit onze studie bleek dat 55% van deze vrouwen met een 50% kans op dragerschap 
en 43% van deze vrouwen met een kans van 4,3% (op basis van kiemcelmozaïcisme) geen 
moleculair onderzoek heeft laten uitvoeren. Meestal wordt DNA-onderzoek bij jonge meisjes 
niet verricht tenzij het consequenties heeft voor het kind op het moment van de test. Bij 
dragerschap onderzoek naar Duchenne/Becker spierdystrofie wordt gewacht tot het meisje 
volwassen is, zodat ze goed geïnformeerd zelf een beslissing kan nemen. Ook als we alleen 
de vrouwen ouder dan 16 jaar selecteerden bleek 34% met een 50% kans en 30% met een 
4,3% kans geen DNA-onderzoek te hebben laten uitvoeren. 
We concluderen dat één op de drie volwassen vrouwen met een verhoogde kans op dragerschap 
geen DNA-test heeft gehad. Verder onderzoek is gepland om de redenen te achterhalen 
waarom zoveel vrouwen niet onderzocht zijn ondanks de verhoogde kans op een zoon met 
DMD en de kans van 10% op hartklachten. 
Wat heeft 26 jaar prenataal onderzoek naar Duchenne spierdystrofie 
opgeleverd? Een overzicht waaruit blijkt dat een tweetal wijzigingen van 
het huidige beleid zinvol zijn teneinde de incidentie van DMD te verlagen.
In hoofdstuk 4 geven we een overzicht van 26 jaar (1984-2009) prenataal DNA-onderzoek 
naar Duchenne en Becker spierdystrofie in Nederland. Er waren 635 DNA-onderzoeken 
tijdens de zwangerschap verricht; in 51% bleek het ongeboren kind mannelijk. Bijna de 
helft (46%) van de jongens was aangedaan of had een verhoogd risico op Duchenne/Becker 
spierdystrofie. Dit leidde tot het afbreken van 145 zwangerschappen, daarnaast werden 174 
niet-aangedane jongens geboren. Het invoeren van DNA-onderzoek tijdens de zwangerschap 
heeft er voor gezorgd dat ouders in geval van een jongen niet meer voor de moeilijke keuze 
van een mogelijke abortus staan, zoals voor 1984, waarbij er een kans was een gezonde jongen 
te aborteren. Voor een klein aantal families bood pre-implantatie genetische diagnostiek 
(embryoselectie) de mogelijkheid om kinderen te krijgen zonder een kans op abortus.
Om de vraag te kunnen beantwoorden of prenataal DNA-onderzoek naar dystrofinopathie 
de incidentie heeft beïnvloed, hebben we de incidentie van DMD in de jaren 60 vergeleken 
met die in de jaren 90. Er was geen significant verschil tussen de eerste (1961-1974) en de 
tweede (1993-2002) onderzoeksperiode. Wel bleek dat het percentage families waarin de 
Duchenne patiënt de eerste was in de familie toenam van 62% in de eerste periode naar 88% 
in de tweede periode. Er was dus geen afname van de incidentie maar de Duchenne families 
maakten wel gebruik van prenataal onderzoek om de geboorte van een tweede aangedane 
jongen in de familie te voorkomen. De meeste DMD patiënten die geboren werden tussen 
1993 en 2002 waren de eerste met deze ziekte in de familie.
In 12% van de families was er al een oudere aangedane DMD patiënt. Er was echter geen 
gebruik gemaakt van prenatale diagnostiek door het zwangere paar, meestal omdat zij niet 
wisten dat dit mogelijk was. In bijna de helft van de paren werd dit veroorzaakt door de nog 
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Als DMD screening in de hielprik wordt opgenomen, wordt de diagnose wel eerder gesteld. 
In Nederland is tot nog toe DMD screening niet opgenomen in de hielprik met als één 
van de belangrijkste redenen dat deze ziekte nog niet te genezen is. In 2011 is echter wel 
taaislijmziekte screening opgenomen in de hielprik, terwijl dit ook een nog niet te genezen 
ziekte is.
Als tweede belangrijke punt vonden we in onze studie van 26 jaar prenataal onderzoek naar 
Duchenne spierdystrofie het volgende:
Ongeveer 78% van de geboren meisjes met verhoogde kans op dragerschap voor DMD, die 
ten tijde van onze studie (2009) tussen de 16 en 26 jaar oud waren, hadden zich nog niet 
gemeld voor DNA-onderzoek naar dragerschap. De gemiddelde kans op dragerschap van 
deze nog niet moleculair onderzochte meisjes was 28%. Dit percentage is lager dan 50% 
onder andere omdat tien meisjes een kleinere kans hadden van 4.3% op dragerschap vanwege 
mogelijk kiemcelmozaïcisme. Volgens de huidige richtlijn kunnen meisjes zich pas laten 
testen als ze volwassen zijn. Dit betekent, dat bijna driekwart van de ouders twee decades 
nadenken over hoe en wanneer zij hun dochter het beste kunnen vertellen over hun kans 
op dragerschap voor DMD. Terwijl door sneller testen al veel eerder zou kunnen blijken 
dat meeste dochters geen DMD draagster zijn. Deze niet wenselijke huidige situatie kan 
voorkomen worden door de ouders de keuze te geven hun dochters al eerder te laten testen 
op dragerschap, dus voordat zij volwassen zijn. 
Een ander argument dat pleit voor het loslaten van het geldende beleid is:
De hielprik bij pasgeborenen is in de laatste jaren in Nederland uitgebreid van drie naar 
achttien ziekten. Bij twee ziekten kan de uitslag zijn dat de pasgebore drager is van een ziekte 
(erfelijke bloedarmoede en taaislijmziekte). In zo’n situatie zou het kunnen gebeuren dat 
ouders wel horen dat hun pasgeborene draagster is terwijl van oudere kinderen in het gezin 
gezegd wordt dat het beter is om te wachten tot het kind volwassen is en zelf kan beslissen 
of het dit wil weten. 
Het is invoelbaar dat ouders in die situatie vragen om testen op dragerschap van het andere 
kind.
Becker spier dystrofie patiënten met een deletie rondom exon 51
Hoofdstuk 5 gaat in op de veelbelovende ontwikkelingen op het gebied van de (op de patiënt 
afgestemde) therapie bij DMD. Theoretisch gezien kan 83% van de Duchenne patiënten baat 
hebben bij exon skipping therapie, het skippen van uitsluitend exon 51 kan toegepast worden 
bij 13% van de patiënten. Gedetailleerde beschrijvingen worden gegeven van drie Becker 
spierdystrofie patiënten met niet-leesraam-verstorende mutaties rond exon 51. Het spiereiwit 
dystrofine van deze patiënten mist een deel maar is wel functioneel. Daarbij is het identiek 
aan het eiwit dat ontstaat na behandeling van Duchenne patiënten met de exon 51 skipping 
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Aanbevelingen in dit proefschrift
Dystrofinopathieën zouden op vrijwillige basis moeten worden aangeboden in de hielprik 
van pasgeboren jongens. Hierdoor wordt de kans kleiner dat er een tweede aangedane jongen 
geboren wordt in de familie. Voor de jongen zelf is een vroege diagnose in de toekomst ook 
van belang. Hij kan dan starten met therapie op maat (bijvoorbeeld exon skipping therapie) 
voordat hij symptomen heeft, waardoor het resultaat, naar verwachting, beter zal zijn.
Ouders moeten de keuze krijgen om hun dochters op draagsterschap te laten testen tijdens 
de zwangerschap als er DNA van de foetus aanwezig is. Ook moeten ouders aangemoedigd 
worden om hun dochters te laten testen, eventueel al voor ze volwassen zijn. Hiermee kan de 
incidentie van DMD gereduceerd worden en het zal voor de ouders makkelijker zijn om de 
dochters te informeren over de toekomstige risico’s. 
Klinisch genetici en genetisch consulenten moeten actiever cascadescreening in 
dystrofinopathie families aanbieden waardoor patiënten en familieleden beter geïnformeerd 
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